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ABSTRACT
Bispecifichybrid-hybridomas have been developed previously frum an anti-
carcinoembryonicantigen (CEA) hybridoma (1 1-285-14) and spleencells fmm mice
inoculatedwithdoxorubicin-bovine serumalbumin(Dox·nSA) conjugate Sevenhybrid-
hybridomaswcreselectedonthebasisof binding to both C'EAand DOX. The purposeof
this study was 10 purifyandcharacterize these antibodies
Each hybridoma was separately injected into Dalb/c mice intmperuoncally and
ascitic fluid collected. The pooled fluid was then Protein A affinity purified and then
further purifiedusing an hydroxylapatite. high pcrfonnance liquid chromatography(IIPI.C)
column. Fractions from HPLC separations were tested using various enzyme linked
immunosorbent assays in order to determine the location of the bispccific antibodies
Positive fractions were pooled and used in microcytostasis assaysusingthe high CEA
expressing(SKCOI) andlow CEAexpressing(COLO 320 OM)celllines. One particular
hybridoma (26-61· 10) was selected for these inzlrmassays. The bispecilic anubody!
DOX testwasableto significantlydecreasethe le wof OOXwith SKCOt . The 1(' .., with
the COLO 320 OM was not altered, illustrating the specificityof the bispecificantibody
for a CEAexpressing ccll line. The specificityof the results were confirmed whenI)()X
wasused inconjunctionwitha non-specificantibody(Ag8) Bispccilic antibodyon its own
or control antibodyon its own, didnot have a significant effecton the viabilityof the cell
lines, This supported the theoryof the bispeciflc antibodydelivering thedrug directly10
the CEA expressing cancer cellsand that the increased toxicitywas not due 10 direct
i ii
antibody killing orcells
T hese results provide the first demonstrat ion that the drug doxo rubicin can be
targetedto a coloniccancer cdlline expressing C EA by a bispeciflc antibody recognising
CEA and the drug
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CIIAPTER I
INTRODUCTI ON
1.0 INTRODUCTIO N
This chapter summarizes the basic characteristics of cancer cell growth and
development. It also provides a discussion on antibody mediated targeting (AMT)
includingthe advantages and disadvantages of its use in chemotherapy. This is followed
by a discussion on bispecificmonoclonalantibodies (BSMab) and methods for their
purification.
1.1 Cancer Cell Growth
In today's world of advanced technology, cancer remains, for the most part, an
unsolved mystery. Great advancesin understanding cancer have occurredwithinthe last
fewdecades but not enough to providea curefor most cancers.
However, research has givenus grcatknowledgeabout cancer and how thesecells
differfrom normalcells. For instance,normaland cancerous cells are very similar in their
biologyofcelldivision and differentiation. Eut, the failure of cells to regulate proliferation,
differentiation and cell-type specificfunctions results in altered phenotypes and cancer
(Fingert et ai, 1993).
Normalcellsreach a steadystate of growth thai provides a balancefor the whole
body. Alltissuesmaintaina steadystate bycontrollingthe rate of cell division, the growth
fraction of the cell population and cell death (Beserge, 1981). Physical stimuli can
positively or negatively regulate the growth rate of cells. In fact, under certain
physiological conditions normal tissue can have a much faster growth rate than that of
cancerous tissue . The difference being, that once repair or healingis complete in normal
tissue the rate subsides to "normal", whereas the neoplastic tissue continues to grow
rapidly(Fingert et el, 1993).
Cancerous cellsgrow at an exponential rate in the early stagesof growth (Skipper
et aI, 1982). This rate slows in the later stages, followingwhat iscalleda Gompertzian
curve (Tennock, 1978). The smallest tumour that can be detected by current clinical
methodscontains approximately109 cells, a I gram tumour that measuresapproximately
I emindiameter (DeVita, 1989). This should beclcnetly derived fromapproximately30
cell divisions. It takes only 10extra doublingsof this tumour to reach a lethal massof I
kg containing 1012 cells. By the time thai a tumour con tains this number of cellsthere is
a very high chance that the tumour has metastasized
Invasion and tumour metastasis impose limitations to the current treatment of
cancer. Approximately 30% of patients with newly diagnosed cancer have clinicaly
detectable metastases. At least 30010 - 40010 of the remaining patients free of clinically
detectable metastases actually harbour occult metastases (Liotta et ai, 1993). Therefore,
over 60% of patients have either microscopicor clinically evident metastasesat the time
of diagnosis(Liotta & Stevenson, 1989) and less than a thirdof newly diagnosedpatients
can potentially be cured by local therapeutic modalities alone (Liotta et ai, 1993).
1.2 Limitation,of Cancer Treatment
There are three main methods of treating cancer: surgery, radiotherapy and
chemotherapy. Surgeryisusedifthe tumourislocalized to a specific organ or primal)'
site.This procedure is associated witha high relapserate due to metastatic seedingbeforc
the time of the surgery. Patients areusually followed up with additional radiotherapy
andlorchemotherapy (Morton. 1993).
Radiotherapy involves the use of ionizing radiation for the production of short-
livedoxygen free radicals insideneoplastic cens. These freeradicals then killcellsvia
oxidation damage (Weichselbaum et ai, 199]), Cell death also occurs due to DNA
damage. Therecan be single or double strand breaks in DNAand alteration or loss of
nucleotidebases(Weichse1b.a.umetai,1993). Excess mutationswill eventually causecells
to undergoprogrammedceD death,Thereare severaldraw backs to thisprocedure, Most
largetumours are oxygendeficient(Jain, 1994) andthereforewillnotcontain manyfree
radicalsonce irradiated Radioresistant clonesmaydevelopaftertherapywhich willnot
respondto further radiationtreatment. Also. there isa problem withexcess irradiation of
"normal" tissue surrounding thetumour,
Chemotherapy onthe other handofteninvolvesthe huravenous injectionof anti-
cancer drugsintothe patient. Someofthesedrugscanalsobeadministered orally. These
drugsacteitherduringsome stageofa cellcycle(i.e. phase-specific orcyclesJlccific) or
irrespective of ceil cycle(l.e. non-cycleactive drugs) {Tsaltas, 1995). Drugsarc also
sortedaccordingtotheir mode ofaction suchas antimetabelites, intercalatingagents and
alkylating agents (E pstein, 1990), Since the introductio n of chemotherapy in the late
1950's, it has madea significant impact in thetreatmentof can cer. It has resulted in at lea st
a 30''10 improvement in survival rates in thepast two decad es, used either in combination
withsurgery and radiotherapyoralone (DeVita, 1989). This success has resulted from the
treatmentoflymphomas,ovarian cancer ,leukemias and seve ralother childhood cancers.
This success rate involves only about 12% of advancedhuman tumours (De vita, 198 9)
However, the common solid tumours such as lung (15%), colorectal (14%), breast and
prostate (2 7%) accou nt for 56 % ofIota I cancer casesand 5 5% of cancerdeaths(Boring
et al, 1991) .
The biggest limitation of current chemotherapyfor cancer is lackof selectivity of
the drugsfor onlythe cancercells(Ford & Casson. 1986). Chemotherapeutic drugs affect
normal. ' fast - growing" cells of a patient. Affected tissues include hairfollicles resulting
in alopecia, bone marr ow causinganaemiaand leukopenia and there isan effecton the
liningof the gastrointestinal traer which causes nauseaand vomit ing(Bushkin, 1993)
Drugssuch as doxorubicin also cause card iac complications (cardiomyopathy) (Young et
ai, 1981). Thereforethere is a needfora therapy that ismuch moreselective10 the tumour
and lesstoxic to the patient.
Another complication of chemotherapy is drug resis tance. Multidrug resistance
(MDR)ismediatedby the presenceofa 170,000 da ltonplasma membrane - associated p-
glycoprotein (Ford et al, 1991). The amount of cell surface expression ofp-glyeoproteins
corre spond to the level of dru gs accumulated int racellularly as well asdrug resistance
(Gerlach et ai, 1986). Drugs suchas verapamil (a calcium channel blocker) cancontrol
multidrug resistance, in somecases,bycompeting with the chemotherapeutic drugfor
binding withp-glyccprctein Tumoursize canalsointlaerce drugresistance The larger
thetumour, thegreaterthe inlerstitiel pressure becomes.This internal pressure, due mainly
to poor internaldrainage andcirculation, causes fluid10 drain awayfromthe tumour
canyingthedrugswith it (Jain, 1994),Thesemmocrs areusually >%emindiamclerand
will not beclinicallydetectableuntilthey reacha diameterof - I ern. Therefore, there is
agrowth period for tumourswheretheybecome resistant to chemotherapyand remain
clinicallyundetectable, Thistime periodmayallowfor additionalmetastases to form
A morerecent formof therapy is Immunotherapy or Biologicaltherapy. This
therapyutilizesvariousbiologica1 agents to fightthediseaseand canbedividedinto active
andpassivemethods,Activetherapyinvolvesboostingthehost's immunesystem against
thetumourwhile passive requires theinfusionofbiologicallyactiveagentsinlo thehost
inordertomediate anantitwoour response,Interest in passivetherapyhas increasedsince
the development of monoclonal antibodies (Kohler & Milstein,1975)and with the
development of recombinant DNAtechnology. Thesetechnologies have enabledthe
development of a wider range and more specific forms of biological agents for
immunotherapy.
:Z.O ANTlBODY·MEDIATEDTARGETING
Antibodies have beenusedas carriers for the delivery of toxins, drugs and
radioisotopesto cancercells,Thetwoessential qualitiesofan efficientanlibody-mediated
targetingsystem are:selectivedeliverycfagentstothecancer site andreducedtoxineffctl
on normalcells (Ford& Casson, 1986, Ford et el,1990)
This conceptof antibody deliveryof toxins to diseased cells was developed nearly
a century ago by Paul Ehrlich (1854-1915). He wasa Nobel Prize laureate who coined the
term "antibody"and proposed his theory on how cells of the body have side-chains
(receptors) (Dale. 1957) and how anti-toxins (antibodies) are produced in order to
eliminate toxinsand stop cell damage. He said that this protectioncould be obtained by
immunizing with bacteria that produced these toxins
Ehrlich alsocoinedthe word "chemotherapy" and because of this, he is considered
10 bethe fatherof modern chemotherapy(Ehrlich, 1908). He realized the needfor better
drug deliverysystems due 10 the nonspecifictoxicity of drugs on normal cells. This
concept was the basisof the antibody-mediated targeting therapy.
2.1 Components or Targeting Therapy
There are threemain components of targetingtherapywhichinclude the target, a
carrier and a toxicagent. The significanceof thesecomponents willbe discussedin greater
detail in the followingsections
2.2 Target Spedfitily
The ideal target cancer cell is one that expresses only one type of antigen. This
antigen has to be specificfor that tissue type or cancer cell.Even though the search for a
tumourspecificantigen (TSA)has been ongoing for the past century. the successof such
research has been dismal (Schreiber et al, 1988), There has been evidence of tumour
specific antigensinhighly inbredmice carryinga tumour inducedby a chemical or physical
carcinogen (Schreiber et al, 1988), but there is no correlation of thesestudies to human
studies. In fact, the only examples of hurnan TSA to date arc the idiotypicmarkers on
certain Ba nd T .::elllymphomas(Stevenson er al, 1990)
The major human tumour markers that have been found are termed tumour
associated antigens(TAA). The best TAA, of course, is onc thaIis expressed ingreater
quantities on tumour cells as compared 10 normal cells. It is also important that this
antigenis not expressed in great quantities on "toxinsensitive"normal tissucsuchas the
bone marrow. gut lining and hair follicles
%.3 Tumour AssociatedAntigens
Three maintumour associated antigens have beencharacterized for major solid
tumours. Theseare: carcinoembryonic antigen (CEA), alphafetoprotein(AFP) and human
chorionic gonadotrophin (HCG). None of these meet the 'ideal tumour marker'
classification perfectly.This classification of a marker is as follows: it should be produced
onlybymalignantcells and detectable in body fluids; it should be useful inscreening and
earlydetectionofcancers;decreasein bodyfluid levelsof the marker should correlate with
the efficacyof therapy (Bates & Longo. 1987).
According to this scheme, ail three tumour associated antigens are equally
important but CEAis probably more applicable to oncologyresearch and AMI. AFP is
expressed highly in hepatocellular and testicular carcinomaswhile I-ICG is expressed in
choriocarcinomas. Testicularcancers and choriocarcinomas have a successful cure rate
of 700/. and >90010, respectively(Chabneret al, 1984), therefore the need for a more
efficient drug targeting systemfor these cancersis not as great whencompared to colon,
lungandbreastcancerswhichhaveverylowcure rates. Thesesolidtumours expresshigh
levels ofCEA and it is thereforean importantmarkerfor screeningand AMT for these
2,4 Obstacles in Using Tumour Antigens for Target ing
There are practical problems that have to be taken into consideration when
developingand testing monoclonalantibodies in AMT. These problemsincludeantigen
expression and shedding, antigenmodulation, antigenheterogeneity, antigendensityand
immunogenicity of the antibody.
2.4(8) Antigen E.pression and Shedding
Tumourantigenscanbemembrane-bound, intracellularor secreted from the cells
Thelevel of intracellular antigensexpressedneeds to be consistentin order for AMT to
besuccessful. Otherwise, theremaynotbeenoughantigenavailable at the surface to allow
antibody-antigen recognition. Eventhough the level isnot alwaysconsistent, studieshave
shown that antibodyrecognitiondoes occur inYiJm (Dairkee et al,1988) and inmn
(Wehetl'l I, 1987).
Antigensheddingon the other hand is the presenceof antigenin the extracellular
space.Thiscouldtheoretically inhibitantibodylocelz ationto the tumour cell and thereby
negativelyaffectlargeting. Studieshaveshown,however, that unlessthe secreted antigen
is in extremelyhighconcentrations, targetingwill occur(Begenteral., 1980).
1.4(b) Antigenic Modulation
Antigenicmodulationinvolves theredistributionof surfaceantigens in the presence
of bivalentantibodies(Cobbold & Waldmann, 1984). Thebivalent binding seems to induce
this rapidprocessandthereforeit decreasesthe internalizationof monoclonal antibodies
conjugated to toxins or drugs(Shawler et al., 1984). However. this may be overcomeby
using univalent monoclonal antibodiessuch as bispecific antibodies
l .4(e) Antigen Htt erogeneity
Most tumour associated antigens are expressed on a proportion of the cell
population(Greiner. 1986). Some cells may not normallyexpress the TAA or cellsmay
have lost the expression due to mutations(Greensberg, 1994). This range of expression
canoccur betweenindividualcellsora tumour and willgreatlyaffect the survival time and
relapse in patients.
One suggested way 10 combat this problem is to use a monoclonal antibody
"cocktail". This includes antibodies recognising varioussurface antigens of a tumour
(Durrant et ai, 1989). Another way to overcome heterogeneity is to use agents which
increase antigen expression. Such agents include interferon (Greiner, 1987). growth
factors and tumour necrosisfactor (Weiner et al, 1988). The use of radionuclidesas a
toxin is another option. This would extend cell death beyond the target cell, thereby
allowing the killof non-antigenexpressers(Order et ai, 1990). However.this would also
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increase toxicity for normal"bystander" cells
2.4(d) Antigen Density
Another relatedtopic isantigendensity. This refersto the density of an antigenon
the surface of the tumour cells. Obviously the higher the density the greater the effect
immunotherapy will have on the tumour. Low levels of expression may result in
subtherapeutic deliveryof antibodies to the target 3ile. As with the heterogeneity problem,
growth factors have been suggested that may enhance the expression of these antigens
Onesuch growth factor is transforminggrowth factor P(TGF Jl) whichhas been shown
to increasethe expressionof eEA on humancoloniccarcinomas (Chakrabarty et at, 1988)
2.4(e) Antibod y Immunog enic:ity
Thisdoes not involvetheantigen but rather the mode of targeting i.e. monoclonal
antibodies. Antibodiesused in targeting research are produced mostly from mice (Ford et
aI, 1987b;Corvalan& Smith, 1987; Cook & Wood, 1994) which becomesa draw back
uponinjecting these antibodies into patients. Subsequent injections will cause the patient
to developan antibody response to this foreign antibody or "antigen" in their circulation.
This response will inevitably neutralize the effectsof the targeting system. This immune
response is known as a HAMA (human anti-mouse antibody) response. The HAMA
responsecould bereduced or abolished by developing eithera human monoclonal antibody
or a "human-mouse"chimeric antibody (Adair, 1992; Ford & Casson, 1986). Chimeric
antibodies are developed through molecular engineering by replacing human variable
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regionheavy andlightchaingenes withmousevariableheavy and light chaingenes (Walls
et ai, 1993).
3.0 DRUG CAR RIERS
There areseveral drug carriersystemsdeveloped 10 date, all of which follow IIset
o f basic requ irements. The carrier should deliver the drug or toxin to the target and
therebyexert itselfect at thai site; the linking of toxin10 the carrier shouldnol impair the
action of the toxinor drug; the complex should remain intact (prolonged half-life) until it
is delivered 10thetarget. Alsothe complex should not be inactivated by the host immune
system (Fo rd & Casson, 1986)
Majo r carrier systems developed to date include monoclonal antibodies and
llposomes. Liposomes are spheresof encapsulating, bitayered phospholipids, Drugs arc
carried inside the liposome and delivered to the target. Even though specificity of
liposomes havet>et:~ increased by attachingantibodies\0 their surface (Tanaka et at, 1989;
Ahmad et ai, 1993), there is still a problem with nonspecific uptake in the
reticuloendothelium system. There is also a problem with toxicityand degradationoft hc
liposomes in ilim (Reddy. 1993)
3.1 Mo noclona l Antibod ies and Cancer Research
There are severaltypes ofanlibody carriers used in cancer research and diagnosis
These include conjugated antibodies, secondary carrier antibodies and blspccif lc
antibodies. Non-conjugated monoclonal antibodies have also playedan importantrole in
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the diagnosis and treatmentof cancer.
Before the developmentof monoclonal antibodiesin 1975(Kohlerand Milstein,
1975) polyclonalantibodieswere used as carriers. These polyclonalantibodiesare not
good carriersforclinical studiesbecauseof antibodyheterogeneityand the host's immune
response to such large quantit ies of foreign proteins. On the other hand, monoclo nal
antibodies haveproducedmuchmoresuccessdue to theirparatopespecificity for only one
particular target antigen. Thesemonoclonal antibodieshave beenused in both diagnosis
and treatment of certaincancers, The treatmentof cancer withantibodiesalone has
includedindirectcytotoxicity relying on the antibodydependentcell-mediatedcytotoxicity
(ADCC) (Redd y.l993)
Direct cytotoxicity includes the use of antibodiesas catalysts to inducechanges
incell membranes and proteinsof cancercells (Iverson& Lerner, 1989) or as regulators
of cell growth(Queenet ai, 1989), Queen et al ( 1989) illustrated how growth-regulating
antibodies, which were specificto growth factor receptors on cancer cells, could be
designed, T hese antibodies controlled the cancer cell growth as a result of binding
competition with the growth factorsthemselves
3.2 Immunoconjugales
Three major chemotherapeutic agents used in immunoconjugates include
radioisotopes. toxinsanddrugs. Theseagents canbeconjugated in a primaryor secondary
fashion
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3.2(s) Radiolabelled Antibodies
Radiolabelled monoclonal antibodies have been used for diagnosis
(radioimmunodetection : RAID) and treatment (radioimmunolherapy : RAIT) of
carcino mas. Radiolabelling of antibodies is considered to be a simple procedure. The
isotopes vary in their half-lives but remain useful in the detection of rnicromctastascs
RAIT has been helpful in the treatment of hepalom as (Order et m, 1()8Sl, Hodgkin's
disease(Lenhard et aI, 1985) and other less common cancers, The underlying problem is
with irradiation of'and toxicity to non-cancerous cells. Studies have beenongoing 10 lind
isotopes withshorter energy path lengths thereby reducingthe levelof'toxicity 10normal
cells. Such isotopes would includea emitters (Macklis et ai, 1988)
J .2(b) Immunetes ms
Immunotoxins areproducedbyconjugatingbacterialor plant toxins to monoclonal
aetibodies. Theoretically, one molecule of endotoxin is enough to killa celland because
of'thisit is considered to bemore toxic than all chemotherapeuticdrugs. The toxin itself
consists of three main sections; "0" side chain (species or serotype antigen) and core
polysaccharide(genus-specificantigen), whichare subsections of the Bcchein, and lipid A
(toxic moiety) (Peterson, 1991). The B-chain or serologic determinant ofthc endotoxin
is removed before the lipidA is covalently conjugated to an antibody. This serological
portion is the cellular moiety therefore removing it reduces the nonspecific binding
(Reddy,I993). Thetoxinitself acts byinhibiting host cell proteinsynthesis. Immunotoxins
have also been developedusing plant toxinssuch as ricinA chain(Shenet al, 1994) and
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diphtheria A chain (Yamaizumi& Mekada, 1978). Such immunotoxins have been used
clinically for cancerssuch as chronic lymphocytic leukemia and B cell leukemia (Hertler
& Frankel, 1989) bUI these immunotoxins have very similar problems to those of
immunoconjugates. These problems will be listed in the next section. However, there are
now recombinant lmmunotoxinsavailable which do not involve chemical linkages. The
gene for the toxin is spliced into a plasmid next to an antibody gene which allo ws for direct
linkage and cost effectiveproduction ofimmunotoxins (Brinkmann& Pastan, 1994).
3.3 Drug Immunoconjugales
Likelmmunotoxlns. drug immunoconjugate (Ie) models have beenwell studied
for cancer treatment. Extensive amounts of information are known about these drugs
including their effect on nonnal and neoplastic cells, toxicity levels and their mode of
action within cells.
To date, manytypes of drug immunoconjugates have been developed and some of
themhave been usedinanimalstudies (Mathe, 1958; Yang& Reisfeld, 1988) and clinical
studies (Eliasct aI, 1990). In order for the IC to be used in a clinical trial, it must first be
proven effective preclinically within.Yi1m (human cells) and in~ (animal model) tests.
These IC s have included various combinations of antibodies and drugs such as:
doxorubicm linked to an anti-proteoglycan Mab (Yang & Reisfeld, 1988), doxorubicin
linked to an anti-leukemic cellPabs (Hurwitz et ai, 1975), vindesinelinked to an anti-CEA
antibody(Fordet ai, 1983) and methotrexate linked 1 ~1 various antibodies (Kulkarni et al,
1981; Deguchi et al, 1986; Garnett et ai, 1983)
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Those Ie 's that do reach the clinicalstage, usually have nOI beenverysuccessful
10 date, for reasons suchas: not enough drug delivered 10 the cells, drug resistanceand
antigenheterogeneity (Kuzel& Rosen. 1994).These problems can be explainedby factors
suchas too few effective drug molecules linked 10the antibody, in mostcases because a
hydrophobic drug is being conjugatedto II hydrophilic protein. The conjugation process
may inactivate the drug itself or the drug may impair the antigen binding abilityof the
antibody (Pielersz et ai, 1989). Studieshave been done in which the conjugationsites of
both the drug and the antibody were controlled. This process can still yield II low
drug:antibody ratio and poor inmm results (Lau. 1994; Lauet ai, 1995 a, b), However.
internalization of such antibodies has been proven inYi.tm using techniques such as
westernblott ing (Tsahas ct al, 1992) and FACS (Ford et aI, 1996)
Conjugates given in mn may be unsuccessful in reaching the tumour. Like
liposome systems, these large antibody-drug complexes may be entrapped in thc
reticuloendothelial system (Pieterse er el, 1994). This will then cause toxicity to the
reticuloendothelial systemwith minimal effects on the tumour.
If the IC arrives in the vicinity of the tumour, it stillmay not enter the tumour in
large enough quantities to totally destroy it. The tumour vasculature may be unevenly
distributed to the point where portions of tumour may not even have any blood vessels
(Jain, 1994). These blood vessels may alsobe convoluted, resulting inslow flow rates in
areas (Pietersz et ai, 1994). This will result in poor perfusion rates and poor conjugate
distribution within the tumour.
Actual internalization of the IC can be slowed or delayed due to antigen
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heterogeneity (Ford & Casson,1986) and increasedinterstitial pressure (Jain, 1994), The
useofMabconjugates with heterogenicantigens willonlydelete a small subpopulalion of
the cells.thusallowingalternate antigen-expressing cellsto flourish. This can be controlled
by using a "cocktail" of Mab's. Interstitial pressure on the other hand, can be controlled
by surgery, if it is possible. As mentioned in section I (1.2), interstitial pressure is a
problem with large tumours (> Y.J em in diameter) and not so in smaller metastatic
tumours. Therefore, with respect 10 interstitial pressures, if all detectable masses are
removed then lC's will be much more effective in clearingthe remaining microfoci of
tumour cells
Asmentioned insectionI 2.J(e), the HAMA response will of course be a problem.
Again, chimeric or humanized antibodies should reduce this problem for targeting
purposes
Inspite of theseproblems. clinical trials have produced some verypositive results
such asa recent study in colon carcinoma (Takahashi et al, 1993). The study illustrated a
muchhighersurvival time of the patients receiving conjugate therapy as opposed to other
chemotherapies. Also,survivalwasincreased when larger doses of conjugate therapy were
given
4.0 BISPECIFIC MONOCLONAL ANTIBODIES
Eventhoughthe productionof bivalent antibodieswas attemptedin 1961(Paulus,
1985). itdidnot gainmuchsuccessuntil the production of monoclonal antibodies(Kohler
& Milstein, 1975)
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Earlyattempts to produceBsMab's byNisonoffandRivers (1961) weredonewilh
polyclonalantibodies usingchemical recombination. The products were therefore highly
heterogeneous providing very low yields of the desired bivalent antibody. Aller
discoveringthat murineB cells couldbecultured and manipulatedinritm,productionof
bispecilicmonoclonalantibodies (Milstein& Cuello, 1983) became muchmore leasible.
Bispeclfic antibodieshavea numberof polentia1advantages over other antibodies
whenusedfor targeting and immunotherapy purposes. Monovalentbinding cf'bispccific
monoclonal antibodies is less likely to cause antigenic modulation of target cells, as
opposed 10 their bivalent counter-pens (Nolan & O'Kennedy. 1990). This monovalent
binding is very important where target cells express the target antigen in very low
densities, Monoclonal antibodies willrequire a fairlydense distribution of antigen in ordcr
to achievebivalent binding. The monovalentbindingof the BSMabwill thereforeallow
more antibodiesto bind to a given cellcomparedto a bivalent Mab. This couldcorrelate
with a greater numberof drug molecules beingdeliveredto the target cell.
Chemicalconjugationofa drug to IU1antibodyto forman antibody-drugconjugate
is no longer required. This eliminates the problem of reducing antibodyaffinityfor the
target and/or reducingthe drug potency
4.1 Bispecific Antibody Produ ction
To date, several techniques have been used 10 develop bispcciflc antibodies
Biological, chemicaland recombinant DNA production methodswillbediscussedfurther
in the following sections.
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4.2 Diological Product ion
This procedure involvesthe use of hybridoma technologythat wasdeveloped by
Kohler and Milstein (1975). Like a normal B cell, a hybridoma expresses an
immunoglobulin with one type of heavy and one type of light chain through a process
called allelic exclusion (Milstein & Cuello. 1983; Songsivilai & Lachmann, 1990)
Bispecific hybridoma proceduresinvolve the fusion of two antibody expressing cells
resulting ina hybridhybridoma (Nolan& OKennedy, 1990). Thesecells secrete a mixture
of parental monoclonal antibodies, bispecificand seven other possible combinationsof
heavyandlight chains(SuresheI al, 1986). This isdue10 a codominant expression of both
heavyand lightchains from both parental cell lines(Milstein& Cuello, 1983).
4.2(8) Bisptcifi( Antibody Light Chain Expression
As mentioned, there are 10 possible combinations of heavyand light chains that
can occur in the cystemal space of a hybrid hybridoma. Figure I illustrates 3 different
types ofassociations. The first involvesa randomassociation of two heavy(HI & H2) and
two light(LI & L2)chains giving the ten listedspecies. Note that only the cis associations
of ~1 andLchains (thosefromthe sameparental cell)can form functional paratopes. The
second type, random heavy chain association, involves complete restriction on chain
assembly. This resultsinthe parentalmonoclonal antibodies(VI & VrI) plus the bispecific
monoclonal (I). The third type of association involves random associationwith partial
restrictionon the light chain. This willgiveantibodies with only one functional arm(II, III,
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IV. & V). Combinations VIII. IX.& Xare completely nonfunclional
Eventhough thebispecific combination is onlyone oul of ten possibilities. reports
iOOicate that the perceuage crseceed bispecific antibodyfrom these hybridomascan vary
from 30'1. to SO-;' (Suresh et ai, 1986.)
Surcsh et al (19868) demonstrated thaI ion exchange chromatography purified
bispecific anlibody ascites into 3 peaks. 80 S· PAGE indicated thai peaks #1 and /I] were
thetwo parentalantibodies, while peak #2was the bispec:iI1c antibody. Other studies have
indicated several peaks and light chain compositions from I-InC purified ascites [Xiang
et ai, 1992; Van Dijk et al, 1989). The differences between these two situations may he
dueto randomcombinations of lighl chainsor eventhe typeof purification procedure
used. Eitherway, it illustrates thefact that all hybrids do nol express a set number onish i
chaincombinations
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Figure J_Expected molecularspecies in hybrid hybridomas arising by random association
of heavyand lightchains. The parental antibody chain compositionsare HIL I and H2l2
and rbese functional associations are boxedor circled, while the presumed fl'Jnfunctional
combinations are not (modified fromSuresh et ai, 1986a)
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4.2(b) Bispcdfi c lIy bridoma Produc tion
There are two basic biological procedures for producing bispecificantibodies
Theseinvolvehybridomaxspleencell fusionor bybridoma x hybridoma fusion(Songsivilni
& Lachmann, 1990), The difference between the two procedures is thai the second
requires the fusion of two well-established hybridomas each of which is producing a
different monoclonal antibody. Thesuccess of the hybridoma x spleen fell fusion relics on
the immortalityof a HATsensitivehybridoma and the production of hypoxnnthinc-guaninc
phosphoribosyl transferase (HGPRT) from an immunized lymphoid cell. The second
method requiresthat bothhybridomas besensitized 10 two different biosynthcsic pathways
(Songsivilai & Lachmann, 1990). Therefore. fusion between these two hybridomas will
allowone to compensate the other in both synthesicpathways, This willgive a successful
hybrid-hybridoma.
4.3 Chemical Production
This method requires two well established hybridomas producing two dinerent
functional antibodies, The hybridomas arc not fusedas in a hybridoma x hybridomacell
fusion but rather the two different antibodies are purified separately and chemically
modified to allow for bispecific antibody formation. This can bedone by coupling two
wholeantibodiesand/or derivatives or by dissociation and reassociation of heterologous
immunoglobulins (Songsivilai & Lachmann, 1990)
The coupling production of'bispecflcs immunoglulins is nol very efficient There
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are problems withdissociationof the chemicallinker and difficultywith the antibody
enteringthe target cells, due to their relative size (CanevariCI aI, 1988). The dissociation
methodrequireschemical manipulationto formthe Fab'fragment (Knuth er al, 1994) for
the formation of derivatives and alsoin the finallinkage step (Brennan et ai, 1985; Vagie
et aI, 1994). This could interfere with the antigen binding site of the Fab fragment and
result in short plasmahalf lives due 10their size.
4.4 Rcc:ombinant DNA Bispecific Produdion
Bispccifie antibodies have been producedusinga recombinantDNA procedure. It
requires that the VIIand VI.genes of twohybridomas be separatelyisolated by Polymerase
Chain Reaction(peR) or by ligating overlappingoligonucleotides(Spooner et ai, 1994)
These are then fused via oligonucleotides which willcode directly for a flexible linker
between the two gene group products. This final product is usually called a functional
single chain bispecific antibody (scFvz)(Gruber et et, 1994) and is usually expressed in
' ..:w:hcri,'hia coli, The placement of the genes coding for scFv1 in the E. coli DNA is
usually in associationwith an amino-terminal secretory signal sequence such as ompA
(Gruber et at, 1994). A similar procedure has also includedthe first constant domains of
each hybridoma (Kostelny et aI, 1992). Either way, the Fe portions are usually excluded
in order to avoid potential HAMA responses inclinical trials
Theprocess itself is verycost efficient and isnot very labour intensive. However,
the tong-term stability of these molecules is unknown (Spooner et ai, 1994) and the
exclusion of the Fc portion may reduceit's plasma halflife
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5.0 PVRIFICATION OF BISPECIFIC ANTIBODIES
The production cf'bispecific monoclonal antibodies results in II numberof light
chain combinations, as illustrated in section I 4.2(a). The purification of bispccitic
antibodies from mouseascites willincludeIInumberof thcseco mbinations as well as other
ascitic proteins. Theadditional antibodies will be responsible for competitive inhibition
with the bispecificduringinYi..tm as wellas in YiY2 assays. Also. the exact concentration
of the bispecificantibody will beunknownwhilethe other antibodiesremainin the fluid
Irnmunoaffinity purification, which is the first purificationstep. is usually done using II
Protein A column(Van Dijket al. 1989; De Lau et al, 1991; Pimm et al. 19(0), This will
removenon-immunoglobulinproteins insolutionby selectively binding to the Fe portion
of the ant ibodies thereby allowing themto be collected inthe eluate
From this point, several procedures of High Performance Liquid Chromatography
(HPLC) protocols, including hydroxylapatite [Jantscheffet ai, [993 ; Xiang ct al. 1992)
and ion-exchange chromatography (Suresh et al, I986b; Allard et ai, 1992) have been
used, The hydroxylapatite column requires the use of phosphate buffers which favours
long-term storage of antibodies compared to the organic solvents usually used for ion-
exchange chromatography (Stanker et al, 1985). Using organicsolvents would require
dialysing the antibody in organic solvents before the HPLC procedure and dialysing back
to the phosphatebuffer afterwards. Usinga hydroxylapatite columnresults in Icss solvent
changing, less dialysis and therefore less antibody loss through precipitation and
attachment to dialysis tubing
2.
6.0 CA RCINOF.MB RYOS IC AN T IGEN
Carcinocmbryonic antigen isa tumour associated antigen, as mentioned in section
12,3, It is foundon many of the common andmosi lifethreatening solid tumours such as
cclorectal (> 65%). lung (>50"10), pancreas (>60"" ). ovary andbreast (> ]()O/o)(Bates &
Longo, 1987). CEA is I glycoprotein with a molecular weight of 180,000 Daltons a nd it
is normally expressedinembryonicb'Ul.IIbelongs to the immunoglobulin(Ig) superfamily
and ischaracterised as being an intercellular adhesion molecule (Abbas er ai, 1994). T his
adhesive ability will increase the survival and metastatic ability of clrculating CEo"
expressing cancercells The metastatic abilityof coloniccancer cells is further supported
byclinicaldata collectedconcerningcolonicmetastasesof the liver. In thiscase, up to 100
% or lbe metastatic cells expressed CEA (Bales & Longo. 1987). Such metastases have
also shown a higheltprcssion of CEA mRNA (Benchimol et al, 1989).
6. 1 CEA . s a Targd ror Antibody ·""w ia. reITargeting (AMT)
As previously rrentioned. section 16.0. C EAis expressed on the surface orma ny
solidlumours Even though it is expressed to a lesser degreeon some normal tissue, it is
an antigen thai is readily available for largelingpurposes. This antigen hasbeen usedin the
past as a target antigen for anti-CEA immunoconjugales for tumour de tection and
therapeutic purposes. Immunoconjugates labelled with lUI have been shown to localise in
advanced metastatic adenocarcinomas (Ford et et, 1983). Also, anti-CEA antibodies
conjugated to vinea alkaloids ha...e proven succ essful in reducing tumour growth in
ltenograft models(Cassonet al, 1987; Corvatan et al. 1987.1988).
This antigenis byfarthe best available antigen that canbeused for AMT purposes
on colorec tal tumours. Both ·. ~lt inYiJrI:l binding properties andthe inIDs:! therapeut ic
potential o f this antigen has beenshown usingan anli-CEA monoclonal antibodyin our
laboratory (F ord et al, 1985. 1986, 1987a. 1987b. 1989.1 990, IQ()I . 1996; Cassoe ee el.
1987; R:ddy l! Ford. 1993; T sallas et ai, 1992. 1991)
The rationale for using the CEA antigen for AMT in the Oncology Research
laboratory is best summarized by Reddy ( 1993);
I. Increased CEA expression on the cell membranes and cytoplasm of thecommon so lid
tumours su ch as colonic, lung and breast cancers, which are presentlyrefractory to
therapy.
2. II is the b est studied and characterized TAA. The CEA pathway froma gene product
to its memb raneexpressionhas beenstudiedand elucidated
3. Many gr oups including ou rs have given proo f of how important these anti-CE A
antibodies are to CEA histopathologyof tumours andin it s ability to bindand inlemali7-c
into CEAexpr essing cells in culture.
4, Ouranti-CEA antibody, 11-285-14, has been proven to localise inmnto xenograns ,
gastroi ntestinal (GI) malignancies in patients and not to becross reactive wilh cro ss
reacting antigens
5. The efficacy of monoclonal anti-CEA antibody 11-285- 14 inassociation with a vinc a
alkaloidand DOXhasbeen shownboth inWm and inriYll using a nudc moose lIcnograft
model
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6. The production or BSMabsspecificto CEA and DOXhas beencomplementaryto
previousimmunoconjugatestudiesdone inthe laboratory.
7.0 DOXORU RICIN
Doxorubicin isoneofthe mostwidelyused chemotherapeutic drugs . withproven
therapeutic effectson a wide variety oftumours [Skladanowski & Konopa, 1993; Myers
et aI, 1986). This drug has had success against a broad range of human malignant
neoplasms including acuteleukemia, non-Hodgkinslymphomas, breastcancer, Hodgkin's
disease and sarcomas(Keizeret al, 1990). DOX isactually an antineoplastic antibiotic
which was isolated froma cultureof Streptomycespeuceuusvar. cae.r i ll S andcan be
producedby chemical synthesis fromdaunorubicin(Vigevani & Williamson,1980). There
are several reportedmechanisms of cytotoxicitythatare attributedto DOX. Probably the
most reported methodof cell killby DOXis by DNA intercalation whereby the drug
preventsthe replication orONA andtranscriptionof RNA(Epstein,1990). This type of
cell killis saidto resemblethat of apoptosis(Skladanowski & Konopa,1993). Another
methodof cellkill byOOX is throughthefonnationof freeradicals.OOX canform an
ironcomplexwhichinduces the formationofhydroxyland oxygen freeradicals. The free
radicals inducelipid peroxidation whichaffects manyof the organelleswithinthecell. This
can causecellmembrane damagewhich leads to celldeath (Keizeret al, I990), 11 is the
actions of thesefree radicals,compounded with the fact that heart tissuecontainslarge
numbers ofmilochondria, low levels of superoxidedismutaseand catalaseand a low rete
of glutathioneturnover, whichaccounts for cardiomyopathywhenusingthis drug(Keizer
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eta l, I990).
Thereare sideeffects and limitations to using DOXfor chemotherapy.However.
the d elivery of the drug to the tumou r using an anti-CEAla nti -DOX bispccfic antibody
may increase its efficacy, especiallyagainst metastases
Anti-CENa nti-DOX bispecificmon oclonal antibodies havebeen developed by
Reddy & Ford (1993). The rationalefordeveloping thebispecificmonoclonal antibody
against DOX ca n besummarized as;
I. DOX has widespread applications
2. AMT will increase the amount of drug reaching the tumour (higher selectivity) and
decrease the levelsentering the heart tissue (lower toxicity).
3. Targetingmore potent analogsof DOXmay bepossiblewhen usinga DSMab.thereby
increasingthe efficacy of' theBSMab.
4. BSMah'sovercomethe problem ofchemicallylinking thedrug 10 the antibody thereby
retaining its po tency.
8.0 OBJECTIVES
Theobjectivesof thisresearch project were 10;
I. Produce asciticOuid fromseven hybrid-hybridcrnas which hadbeen selected on the
basis of their reactivitywithCEA anddoxorubicin
2. Affinitypuri fy immunoglobulins from each of the asciticfluids using Protein A
3. AnalyseProteinApurified inununoglobulins from each oft he hybrid-hybridomas using
hydroxylapatite HPLC.
2B
4. Screen HPLC fractions of eachhybrid-hybridomafor anti·CEA, anti·DOX. anti-DOX
.BSA, anti-BSA and dual activity by enzymelinked immunosorbentassays.
5. Select the most promising bispecificantibodies for further investigation (based on I •
4 above)and scale up the HPLC for preparative purification of these antibodies
6. Test the ability of one of theseantibodies to target doxorubicin to CEA expressingor
eEA non-expressing human coloniccancer cell lines using a colorimetric microcytostasis
assay
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CHAPTER II
MATERIALS AND METHODS
II 1,0 BISPE CIFIC HYBRIDOMAS
The bispeclfic antibody producing hybrid-hybridomasused in this thesis were
developed in the Oncology Research Laboratoryby Reddy and Ford (Reddy, 1993;
Reddy & Ford. 1993). These hybrids were selected according 10 their anli-CEA. anti-
DOX anddual activity
II 1.1 Colonic CanccrCell Lines
The coloniccell linesused in this project as lest cell lines included the SKCOI
which is a high CEA expressing cellline 85 well as the COLO 320 DM ~'.'hich is a low
OTnegative CEA expresser (Ford et ai, 1987). These lines were used for inritm assays
(section 116,0) and all wereobtainedfrom the AmericanType Culture Collection
(ATCC) Roc kv ille . Maryl and, U,S.A
II 1,2 Tissu e Culture Maint enance
The hybridhybridoma suspension lines and the coloniccancer monolayer lines
were grown in 75 cml tissue culture flasks (Falcon, Bectcn-Dickinsoe]. These cells
were maintained at 3'PC in a 5% carbon dioxide atmosphere in a humidified incubator
Cell lines were maintained in the required medium as listed in sections 1.5and 1.6. The
3 0
mediumwasreplenisheddaily inorderto maintain optimal growthof cells
II 1.3 Mediu m for COLO 310 OM and the B ispecin c Hybridomas
The coloniccancercell lineCOLO320 DM and the seven bispecific
hybridomasrequired RPMImedium
(I) RPMI. I640 , 500 mt(II 21870.050, GlBeO Laboratories. l ifeTechnologies, Inc.•
Grand lsland, N.Y.)
(2) Fetal caJfscrum (FCS), 50 ml (# 3000, P,A. Biologicals Co. pry LTD., Sydney,
Australia)
(3) Penicillin/streptomycin, 12 ml (#15070·014, GlBCD Laboratories)
(4) Lglutamine, 6 ml (II 25-00S-LI. CELLGRO, Medletech, Washington, D.C.)
II 1.4 Mediu m for SKeO I
(I) Minimalessential medium (MEM), 500 ml(II 11090-057, GlBCa Laboratories)
(2) FCS,SOml{#3000, PA Biologicals CO. PTY LTD.)
(3) Penicillin/Streptomycin, 12 mt (# 15070.014,GlBCO Laboratories)
(4) Lglutamine, 6 ml (# 25.005.LI, CELLGRO,Mediatech)
(5) Non-essential amino Acids, 6 ml (# 25.025·Ll , CELLGRO, Mediatech)
II 1.5 Tryps inization ofcells (for COLO 320 DM an d SKCOl )
II 1.5(8) Materi als
( I) Trypsin-EDTA (x 10)(GibcoLaboratories, Life Technologieslne., Grand
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island, New York)
(2) Phosphate butTered saline(PBS) pH 7,2. I tablet per 100 mldistilled
water. (Oxoid, UnipathLtd.• Basingstoke. Hampshire.England)
(3) Benchtcp centrifuge uec HN 811model)
(4) Conical centrifugetubes,15 ml(Falcon. Becton-DickinsonLabware,
Becton-Dickinson& Company, Lincoln Park. NewJersey, 07035)
L.5(b) Metho d
(I) Dilution (1:10, 5 ml) oftrypsinand PBSwaspreparedaseptically.
(2) Cultures which were confluentbut stillin logphaseof growth werethen washedin
5-10ml of sterile PBSand the washingdiscarded.
(3) Thetrypsin·PBS solution wasadded to the flask and incubated for 10 minutesat
37°C.
(4) Thecell suspension wasthen added 10 a 15 mlconical centrifuge tubeand the flask
washedin 5 mlPBS,
(5) Oncethe flask was washed, thesuspensionwas centrifugedat 1000rpm(220" g)
for S minutes in a benchtop centrifuge.
(6) Thesupernatant was decanted andthe pellet was resuspended in 10 mlME.M. A
viability count wascarriedout as described below.
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1.6 ceu eounl
Viability counts or cells weredone using a fluorescen ce microscope and a
Neubauerhemocytometer, Cells weremixed withan acridine orange (AD)and
cthidiurn bromide (EB) solution. TheAcridineorangestains viable cellsa fluorescent
green while the ethidium bromide willsta in the dead cellsa brownish-redcolour when
viewed under ultraviolet light.
II 1.6(8) Materi a ls
(I) Neubauer hemocytometer(with cover slip)
(2) Acridineorange (AO) (IIA-.60 14, Sigma Chemical Co.,St. Louis, Missouri).
(3) Ethidium bromide (EB) (#E-87 51, Sigma Chemical Cc.). I mlaltquon of
AO and EB (0,001%) weremade up in roc mt of PBSand stored at .200C.
(4) Fluorescent microscope with 50 Watt mercurylam p(OrtholuxII, Leitz).
1.6(b) Method
Cells fromthe culture flasks were transferred to a cen trifuge tubeand
centrifugedfor five minutes at 1000rpm ( 17Sx g). The supe rnatant wasdiscardedand
thepellet was resuspended in 10 mlofmedium. One dropof thissuspension wa s mixed
with one drop of AOIEB solution, Aportion of this mixture was placed under the
coyer slipof a hemocytometer and placed under a fluorescent microscope, Countswere
then done and the percent viability was calculated as given:
% viability = (torelAD count! totalcellcount)x IO()OID
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1.7 Cry oprnt'n'I CKtn orCtib
II 1.7(a) :\olAlt rialJ
Freezing mediaconta ins100/ , (1:10) dimelhylsu lfo!'lide (DMSO) (' [}-8771).
SigmaChemical Co.) in fetal calf serum(FCS). This solution was fdtered through a
Millipore 0.22 um syringetiller (Millipore Products. Bedford. MA 01730) andstored
al-2ffC.
1.7(b) Meth od
( I) Cells were counted(sectionsII \ .5& 1.6)
(2) The cells were thencentr ifuged for S minutesat 1000 rpm ( 175 xg)
(3)The supernatant wasdiscarded and lhe pellet resuspended in cold frcc,jog medium
(on ice) at a concentra tio nof S x Io' ce lls per I 101
(4) I 101aliquotswere made. labeled andplacedat .urc overnight
(5)The I mlaliquot! al -' OOC were thentransferred10 liquidnitrogen the
followingday
1.8 Tha winlJof Cells
(I) Medium(9 101) wasaseptically transferred 10 a IS 101 centrifuge tube
(2) Theappropriate vial of cellswas removed fromthe liquid nitrogencanister and
thawedina 31'C waterbath.
(3)Before complete thawing thevial wasquicklytransferred to a flow cabinetand
pipetted into the 9 mIof medium, onice.
"
(4) This mixture was then centrifuged for 5 minutes at 1000 rpm (175 x g).
(5) The supernatant was discarded and cellswere resuspended in I to 2 ml ofmediurn
(6) The cells were then transferred to a 25 em' culture flask and incubated at 37DC in a
humidified, 5'~ carbon dioxide atmosphere incubator.
II 2.0 PRODUCTION OF BSMab ASCITIC FLUID
The selected hybrid-hybridomas from section II 1.0 were thawed as in section II
1,8 and maintained as describedearlier (sections II 1.2 & 1.3). Once the cellshad
achieved sufficient numbers (section II 1,6), the appropriate volumes of cells were
removed and injected into pristane primed mice (section II 2,1), Remainingcellswere
then frozen down 10 approximately 5 x 106 cellsml. Thisprocedure is detailedin
section 11 1.7.
II 2.1 BSMab Production in Mice
II Z. I(a) Materials
(1) t' ristane (# T-7640, Sigma Chemical Co., 81.Louis, Missouri.).
(2) Ethyl ether (# 9249-06, IT.Baker Inc., Phillipsburg, Nl)
(3) Refrigerated centrifuge(Model TJ.6, Beckman Instruments Inc" Palo
Alto. CA.).
(4) 15 ml centrifuge tubes (# OOQ-2097-STR, Elkayproducts (UK) LTD.,
Basingstoke, Hampshire. UK).
(5) 5 01 syringes(# 9604, Becton Dickinson and Co.•Rutherford, NJ.)
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(6) 50 ml centrifugetubes (Fisher Scientific,Ontario)
(7) 20 gauge needles(# 305175. BectonDickinsonandCo.).
(8) Bispecitic hybridhybridomas
(9) Balblcmice(Jackson Laboratories, U.S.A.)
2.I (b) Method
( I) Balb/c micewere primedwith an intraperitoneal injection of 0.5 ml of'pnstanc two
weeksprior to the hybridinjection
(2) Cellswere maintained in culture, as in section 111,2 & 1.3.
(3) Cells were centrifuged(5 minutes, 750 x g), resuspendedin 10ml of mediumand
counted (as in section 111.6)
(4) Suspensions were recentrifuged and resuspendedin sterile PBS at 1,0 X 10" viable
eellsperO.5ml
(5) Each hybridwas then transferred separatelyto 5 ml syringes
(6) Hyoridswere injected intraperitcneallyinto ether anaesthetised. pristencprimed
Dalb/c miceat 0.5 mlper mouse
(7) The mice wereregularlymonitored for abdominalswelling andascitic fluid build-
up. Withdrawal or ascitic fluidstarted around 10 days post inoculation
II 2.2 Tapping of Astiti c «'Iuid
II 2.2(a) Materi als
See section112. I(a)
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II :': (b) Method
( I) Hybrid.inoculalC:d micewere tapped by first anaesthctisin8the animalwith ether.
(2) Theintraperitoneal fluid was removed using 20 gauge needles and S mI syringes
(3) Theascitic fluid fromdifferent mice inoculated with the samehybrid-hybridoma
was drawn into a syringeand pooled in a labelled SOml Ultlrifuge tube (on ice)
(4) Each mouse was then placed into a recovery cage before being transferred back to
its appropriate cage. Mice were not tapped more than three times at which lime
theywere terminated, Any animalnot looking well was also terminated.
(S) Once withdrawn, the ascitic fluid was centrifuged (10 minutes. 4000 rpm, 750 x g).
(6) The supernalant was then removed and pooled inappropriately labelled bottlesand
stored at -200c.
II J.O PVRIFICATION OF BS~bb FROM ASCITIC fLU ID
II 3,1 Prolrin A-5tphuosc Affinity Column Puri fication
Protein A isa bacterial cell walt protein of SlOphyJococclls al/rells. 11 is a single
polypeptidechainof 42 kDa with glyccproteine(HermansoncI al, 1992). It is classified
as a type I bacterial Fe receptor according to the Myhre and Kronvallclassificationof
bacterial immunoglobulin-binding proteins (Boyle, 1990). Mouse IgO. does not bind to
this protein as wellas Ig0 z., IgG2b oil (Hermanson et al, 1992), whereasProtein0 is
noted as beinga better binding proteinfor themouse IgOI subclass. However,
according to Western blotting results obtained in the OncologyResearchLaboratory,
use of Protein0 did not resultin anybette! purification of lgO. than didProtein A
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(unpublishedobservations). Also, ProteinG is not recommended for the purification of
mouse IgO. as its removal fromProtein G can bedifficult (Andrew& Titus. 1994)
Therefore, Protein A was used 10purify the sevenBSMabs from ascitic fluid in this
investigation.
II 3.I( a) Mat erials
(I) Purification buffers:
A. 0.5 M sodiumphosphatebuffer pH 8.0. Sodiumdi-hydrogen
phosphate (monobasic) , NaHlPO j • Hp (II ACS 795, BDI~ Inc .•
Toronto) 69.0 g/L, di-sodium hydrogenphosphate. anhydrous.
Na2HPO~ (N830 158, BDH Inc.) 71.0 giL with 0,01% sodium
azide, NaN] (N830 III , BDH Inc.). 69 g of' phosphate
monohydrate and 0 ,1 9 of sodium azide were dissolved in I litre of
distilledwater. This was added to an anhydrousphosphatesolution
(71.0 gi n- 800 ml of distilled wate r with 0.1 g orsodlu mazide)
This mixture was adjusted to pH 8.0 and made up to 2 1itrcs in
distilled water. Th is stock was stored at -20 DC . The required 0. 1 M
buffer was obtained by diluting the 0.5 M solution 1:5 in distilled
water.
B. 0.1M citrate -phosp hate buffer pH 3 .0~7.0 . Citric acid, Ct,Hw0 1 I
Hp (# 827 780. 8DH Inc.) 21.01 giL, di-sodium hydrogen
phosphate. Nal HP04(BDH tnc.) 0.1 M. 14.2 giL. A O. J M citric
J8
acid solution was obtained bydissolving 21.01 g of citrate crystals
in I litre of distilled water. The pH 6.0 buffer wasmade by
titrating the0.1 M phosphate solution with the citric aciduntil the
desired pH was obtained. The pH 3.5 solution wasobtained by
titrating thecitric acid solution with the phosphate bufferuntil a pH
of3 .5 was obta ined
C. 1,0 \t: Tris-hydrochloric acidbufferpH 9,0. Tris(hydrOlcymethyl)
aminomethane I M( # T-1503, SigmaChemicalCo.) 121 gIL,
Hydrochloric acid 1 M . Dissolve 12 1 gofTris in Ili tre of distil1ed
water. Mix2S mlof 1 M Triswith2.5 ml of J MHel while
Titratingto a pHor9 .0.
(2) PBS
(3) Whatman # 2 filters (Whalman Industries Lid" Maidstone, England),
(4) Sterile 0.22 11m filter (M illipore Corpo ration, Bedfo rd, Mass.)
(5) Amiconultrafiltration unit (Amicon Corporation. Lexington. Mass.)
(6) Spectrophotometer (BeckmanInstruments INC.).
(7) PHM82 standard pH meter (Bach-Simpson Limited, London. Ontario).
(8) Gel filtration column (Phannacia column length30 em,diameter 2 em).
(9) Peristaltic pump p.) (Phannacia FineChemicals. Uppsala,Sweden)
(10) Protein A-Sepharose48 (Pharmacla Fine Chemicals)
( I I) Dialysis tubing(SpectraIPor Membrane MWCO 12.14,000. Spectrum
MedicalIndustries. fnc., Houston. Texas).
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(12)Pressurizedfilteringapparatus (Millipore Corp.).
(13)Filtering membranes; 1.2 pm, O.45 l!ffi,0,22 11m tillers,membmne spacers
and prefilter membranes (MilliporeCorp.).
J. l(b) Protein A Column Preparano n
(I) Freeze-dried Protein A powderwasswollenin O. I Msodium phosphatebuffer (pH
6.0)
(2) The swollen beadswere washedon a 15 ml sinteredglass tiller funnel
(3) The beads were then resuspended inphosphatebuffer (pH 6.0) and poured intoa
30 mlPharmacia column.
II J. t (e) Ascitic Fluid Filtratio n
(I) Each of the pooledascitic fluidsamples was thawedand passedthrougha
Whatman#2fi1ter.
(2) The volumeof'the filteredsamplewasmeasured andthendilutedin 3 volumes of
0.1 M sodiumphosphatebuffer.pH8,0 (at 4°C)
(3) The ascitic fluid was filtered using a Milliporepressurizedfilteringsystem, The
series of Milliporefilterswereset up in the following manner: Iirst, a pre-filter
followed by a spacerthena 1.2 urnfilter, a spacer, a 0.45 pm fiher, a spacerand
finally a 0.22 11m filter.
(4) The filtered ascitic fluidwas thenremovedfromthe apparatus asepticallyand
stored at _20°Cin approximately50ml aliquots
II 3.J(d) Purificalion
( I) The protein A column(section # II 3. I(b» was equilibrated by washing with
phosphate buffer. pH 8,0 at 41fC until anO ,D. reading of'< 0,02 al 280 om was
obtained
(2) Whatmanfilteredascitic fluidwas then added (25 ml) 10 the columnallowingall the
material to run into the gel. Theunabsorbed material was collected. labelled
NONBOUND MATERIALand stored at .200C.
(3) Once the ascitic fluid had entered the gel an equal volume of phosphatebuffer pH
8.0 was added, The collected eluate was labelled WASH#1 and stored at _20°C.
Both the NONBOUNDand WASH #1could be pooled and repurified later
(4) The columnwas then washedovernight with phosphate buffer pH 8,0. This
was continueduntil the D.O, of the eluting fluid was < 0.02
(5) Anequal volume or o.I M citrate/phosphate bufferpH 6,0 was then added to the
column. Eluted antibody was collected using a flask containing 1 ml of 1.0 M Tris
bufferpH 9,0 to immediately neutralize the pH. This fraction was labelled pH 6
ELUTED andstored at _20°C.
(6) The remaining bound antibodies were eluted using an equal volumeof 0.1M citrate
bufferpH 3.5and collected in a separate flask
(7) The collected pH 6 ELUTED samples. for each batch of ascitic fluid. were pooled
and concentrated to approximately 2 to 3 mglml using Arnicon ultrafiltration
(8) At the same time the column was washed with phosphate bufferpH 8.0 until the
0 .0 . was < 0,02.
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(9) The concentrated antibodies were thendialyzed against 3 changes of cold PUS
Each session was about 8 hours
(10) Thedialyzed solution WIS then transferred to a sterile tube. It was then
filtered using a 0.22 um Milliporefilterand a 00 reading taken Thesample WIS
then labelledand scored er 4OC.
( I I) The NONBOUNO and WASH#I were pooled and repurified by Protein A column
chromatography 10 check for any bispecific antibodies that may not have bex n
bound 10 the column during the first application
3.2 IIIgh Performance Liquid Chroma tography (HPl C)
HPl C was used as a final purification procedure for the bispecific monoclonal
antibodies. Each purifiedasciticfluid sample was analyzedusing HPLe andfurther
analyzedaccording 10 iu HPLC separalion absorbance (280 nm)profile:. One minute:
fractions were taken of each HPLC separation. Fractions corresponding 10particular
HPLC peaks were further analyzedusing ELISA
II 3.2(.) M.I~ri. ls
( I) Hydroxylapatite column and guard (BIO-RAD Laboratories (Canada) Ltd.,
Mississauga)
(2) Phosphate Buffers
A. 60 mM, pH 6.8. NaH1PO" HJO (N ACS 795. DOH Inc.) 0.704 WI.
sodium phosphate (dibasic) NaJHPO" 1 HID( II 5373-500, Fisher
"
ScientificCo., Ontario) 1.314 g dissolved in I litre of distilled water.
The pH was adjusted 10 6.8 using 2.0 M NaOH
B, 180 mM, pH 6.8. NaH2PO~ (BDH tnc.) 4.22gil, Na2HPO~ (Fisher
Scientific) 7.88 g dissolved in I litre of distilled water. The pHwas
adjusted to 6.8 using 2.0 M NaOH.
C. 360 mM, pH 6.8. NaHIPO~(BDH Inc.) 12.66 g. Na2HPO~ (Fisher
Scientific)23.64 8 dissolved in 1 litre ofd isti1led water. The pHwas
adjustedusing 2.0 M NaOH.
All of the above buffer solutionscontained 0.05% NaN)(# 83011 1, SOH Inc.)
O.Sgil and 0.01 roMcalciumchlorideCaCI1 {# 1-1308,1.T,Baker Chemical Co.)
0.00111gil. Solutionswerevacuum suctionfiltered through 0.44 urnand 0.22 pm
filters and stored at 4nC.
(3) HPLC analog interface module 406, Programmable Detector Module 166,
Autosampler 507, IIOB Solvent DeliveryModule (System Gold Model
460AT. BeckmanInstruments (Canada) Inc. )
(4) Nylon filter membranes 0.45 urn (CAT # N0 4SP04700) and 0.2211m(CAT
# N02SP04700).Micron Separations Inc., Westboro, MA. C/O Fisher
Scientific.
(5) Suction filtration funnel
(6) Suction flask (Pyrex, U,S.A)
(7) Heliumgas
(8) Nitrogen gas
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(9) Fraction collectorwith glass test lubes (PharmaciafractioncollectorFRAC·
100, Phannacia Fine Chemicals)
II J .2(b) Method I
HPLC and hydroxylapatite columnshave been used previouslyfor purifying
bispeciticantibodies by Xiang et al, 1992 and Dietsch et aI, 1993. The following
methods involve slight modifications of these procedures
( I) Both the 60 roM and the 180 roM phosphate buffers weredegassedfor len minutes
eachusing helium gas
(2) Each buffer sampleline was then bled inorder 10 clear the systemof air bubbles.
The pump pressure was immediately set to aptauximately500 psi.
(3) Vial containing the protein A purified bispecificascitic fluid samplewas placed in
the assignedposition on the autcsamplercarousel.Then, the nitrogen gas was
turned on, which wasneededto activate the sampling apparatusin the autosamplcr
(4) Theappropriate file was then activatedon the SystemGoldsoftware program. This
stepstarted the HPLC procedure. Thecomputer controlledthe restort he
procedure, analyzedthe resultsand stored the results in the file that was activated.
(5) The autosampler removed the presetvolumeof ascitic fluid from theappropriate
vial and loaded it onto the column.
(6) At the same time the loading buffer(60 mM) was being pumped by pump #1
(100 %) at a preset rate of 1.5 mVrnin. Thiscontinued for 20 minutes
(7) Pump #2 was activated,removing 180mM eluting buffer from a second flask.
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Bufferwas pumpedfrom0 % to 100% over a 80 minuteperiod. Pump#1changed
from 100 % to 0 % over the same timeperiod. This resultedin the 60-J80 roM
phosphate buffer gradient
(8) Atthe onsetof the HPLC analysis I mVmin fractions were collectedeveryminute.
Thesefractions were then used for ELISA.
(9) Oncethe analysis was completed the gradient was reversed and the column was
equilibrated 10a baseline0 ,0 . oro
II 3.20 Mrlh odll
This procedure was the same as II ] ,6 (b) Method I with the exceptionof using
a 360 roMelutingphosphatebuffer insteadof a J80 roMbuffer.
II 4.0 DOX - USA CONJUGAT ION
Doxorubicinwasconjugated to bovineserum albumin (BSA) using ECDI [J-
ethyl-J-{dimethylaminopropyl) carbodiimide] as a heterobifunctional crosslinker. BSA
was the carrier macromolecule usedduringthe immunizations with DOX.BSA, which
had beenused for the developmentof the hybrids being used in this thesis (Reddy &
Ford, 1993). The following conjugation method is a modification ofa procedure
previously developed in the Oncology Research Lab (Reddy, 1993 ; Reddy & Ford,
1993).
II 4.0(a) Materials
( I) Doxorubicin hydrochloride (Adriamycin Hel ; Adria laboratories Inc.
Columbus, Ohio)
(2) Phosphate buffered saline(PBS)
(3) ECDJ ( I • ethyl. 3 • (dimelhylaminopropyl) carbodiimidc I. (/I E·6J8J.
SigmaChemical Co.)
(4) BSA(A. 7888, Sigma Chemical Co.)
(5) Spectrophotometer (Beckman Instruments(Canada) Inc.)
(6) Olasscuvettes(Beckman Instruments(Canada) Inc.)
II 4.0(b) Mefhod
(I) 70 mgorB SA was dissolved in 2 ml of PBS (made from tablets; Oxoid). This was
left at RT for I\12 hours to dissolve.
(2) 2 ml of DOX (2 mglml)wasadded10theBSA solution dropwise, withoccasional
lightstirring.
(3) ECDI (15 mg in I ml of PBS; pH 7.2) wasadded dropwise10the DOX·
BSA solution, with occasional stirring. Thismixture was thenleft at RT for 4
hours (covered in aluminumfoil) and gently stirred every30 minutes
(4) The finalpH of the solution was 6.78. The solution was stored a14"C
overnightand then at RTfor 2 hours in order to redissolve the precipitate that
formed overnight
(5) The solution was then slowly added to a Sephadex 0 - 25 gelfiltrationcolumn (see
sections" 4.I(a) & (b)) . usinga Pasteur pipette
(6) Fractionswerecollected everyfiveminuteswith a total or50 fractions collected
The conjugate was eluted usingPBS.
(7) Theabsorbanceof each fractionwas thenanalyzedat 280 and 495 omusing a
spectro photomete r, The molar rat ios were calculated as follows;
where; A1 1'1= absorbance readingat 280om
A2~n'= calculated absorbancereading for DOX at
2S0 nm
Am"= true absorbancereadingfor BSA at 280 om
Am = absorbance reading at 495 om
c = molarconcentrationof DOX
c'= molar concentration of BSA
13,000 = extinction coefficient of DOX 31495 om(Dement & Sehested, 1993)
8,000 = extinction coefficient of DOX at 280 om(lau, 1994)
44,200 = extinction coefficient or BSAat 280 nm(Dement & Sehested, 1993)
The concentration of DOX at 495 nm:
A~._,'" 13.000(c)
solve for c.
The concentration of DOX al 280 nm
Al'''' '" 8,000 (c). solvefor A1f.{l'
The true absorbance ofB SA al 280 nm;
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Theconcentration orBSA'
AlIo• ""'44,200 (c'), solve for c'.
DOX: BSAratio'
C (DOX) , C'(BSA)
II 4.1 Gel Filtralion
II 4.1(8) Mater ials
(1) SephadexG25 (# 5C202722.Pharmacia FineChemicals. Uppsala. Sweden)
(2) Gelfiltration column(Pharmacia column, Length 30 em, diameter 2 em)
(3) Peristalticpump P-3 (Pharmacia Fine Chemicals)
(4) Fraction collector with glass test tubes (I'harmacia programmable fraction
collector FRAC- 100. Pharmacia Fine Chemicals).
(5) Pasteur pipettes
II 4.I(b) Method
( I) SephadexG · 25 superfine beads were used at a predeterminedconcentration of I
g to 5 ml of PBS. The amount used in the30 emcolumn was 12 g in60 rnl of
PBS .
(2) The beads were expanded in PBSat 4°Covernight
(3) The column was poured in the cold room(at 4"C). A peristaltic pumpW<!'l attached
to allowfor aneven now rate for fraction collecting(I mVminute)
"
II 4,2 CEA·IIRP Conj uga te Production
This conjugatewas produced inorder 10 test the dual activityof the bispecific
monoclonal antibody.
II 4.2(a) Materials
( I) Carcinoembryonicantigen (CEA)(supplied byOncologyResearch
Laboratory and purifiedfromliver metastasesas publishedby Ford et at ,
1987b)
(2) 0.01 M sodium carbonatebicarbonate buffer, pH 9.5:
(a) sodiumcarbonate 5.3g (# AC·8290. Anachemica Ltd .• Montreal) in
500 ml distilled water (J M solution)
(b) sodium bicarbonate 4.2 g (N7412, Mallinckrodtlnc., Kentucky) in
500 ml distilled water (1 M solution) 25.4 mlof (a) was added to
74.4 ml af(h) and made up to I litre.
(3) 1% Dinitroffuorobenzene (N0 ·6879, SigmaChemical Co.). 100 ~ l in 10
ml of absoluteethanol.
(4) 0.08 M Sodium periodateNaIO~ (# 1867070, BOH Chemicals, England)
17.12mgdissolvedin I mlofd isti11ed water.
(5) Ethylene glycol monoethylether(# E-180, FisherScientific Co., New
Jersoy j. 16 IIIEthyleneglycol in 10 ml of water.
(6) Sodium borohydride NaBHl (2 mglml)(# S·9 125, SigmaChemical Co.)
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(7) Horseradish peroxidase. Hydrogee-percxtde oxdo- redocuse, TypeVI.
(Sigma ChemicalCo.)
II 4.2(b) Met hod
Thi s procedurewas previously usedby the Oncology Researchgroup 10 label
11-28S-14 monoclonal antibodies with HRP (Woodhouse. 19&21).~ procedure was
slightlymodified by Reddy, 1993. in order to label the CEA with HRP.
(1) To6.2 mgofHRP (type VI, RZ=3)in I ml carbonate butTer (0.01 M). 100 111of
1% dinitrofluorobenzene inabsolute ethanolwas added and stirred gently for 2 hrs
aI RT .
(2) I mJ orO.08 M sodium periodale was added 10 the solution followed by gentle
m:xing for 30 minat RT.
(3) This was followed byadding J ml of 0.16 M ethyleneglycol
(4) Themixture was then stirred for 1 hr al RT anddialyscdagainst three changcsof
carbonate bufferat 4OC.
(5) CEA I my'ml in carbonate buffer wasadded 10 the above solutionand mixed gently
for 3 hrsat RT.
(6) Subsequently, 4.1 ml of sodiumborohydride (2 mwml) was added and the solution
dialysed against PBSovernight at 4°( .
(7) The CEA·HRP conjugate was separated from free HRPusing a SephadexG-75 gel
filtration column (section 114.1(a) & (b) using SephadexG~15 instead of G-25).
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I I 5.0 ELISA
II 5.1 Int roduction
Enzymelinked immuaosorbent assays are assays used 10 test the specificity of
antibody-antigen reactions. ELlSAs have an advantage over radioimmunoessays in that
no radioactive substances are required. Also. the reagents for ELISA arc less
expensive and can be stored for long periods of time
An anti-CEA ELISA was developed by Woodhouse et al (1982b) using micro
cuvettes. Reddy ( 1993) modified this procedure and developed procedures for anti-
DOX, anli-DOX-BSA and anli-BSA detection. He also developed a procedure for a
dual assay using a CEA·HRP conjugate. These procedures are listed below.
II 5. 1(8) Mater ials
( I) 8 channel digital micro pipett e (Model 7000, Nichiryo, Japan)
(2) 2,2 - Azino - bis (3 - Ethylbenethiazoline- 6 -Sulfonic Acid) (ARTS) (# A·
1888, Sigma Chemical Co.).
ASTS was prepared as stock at 27.8 mg/mt ABTS solution was made up
in 100 ml of distil1ed water, aliquoted out in 100 ilL samples and stored at
.20,1c. Freshly prepared 0.2224 gIL of An TS as substrate for each ELISA
contained 100 ul of ARTS stock, 12.5 ml of citrate phosphate buffer. and 1
ul of hydrogen peroxide
(3) Hydrogen peroxide, 30% (N ACS 399.74, DOH Chemicals co., Toronto,
Cenada.j.
(4) Rabbitanti-mouse immunoglobulins labelledwith HRP (RAtIol .HRP)(I'16I ,
Dako, Denmark)
(5) ELISA96 well Microtitmtion Plates (l eN Biorncdicals Inc.)
(6)ELISAbuffers
A.Citrate phosphatebuffer, pH4.0. Citric acidcrystals (# 013402,1.T.
Baker Chemical Cc., Philipsburg, New Jersey, USA)4,53 B ' sodium
hydrogenphosphate(# 114288, BDHInc" Toronto, Canada)
NaIHPO.5.083 g, This wasdissolvedin double distilledwater, pll
adjusted to 4,0 with 12 M Hel and made up to a final volume or
500m l
B, Carbonate - Bicarbonatebutler, pH9.2, sodium carbonate ( AC -
8290, BDH I!'!t') NalCa, 0,795 g, sodiumbicarbonateIS - 8875,
Sigma Chemical Cc.) NaHCO, 1.465 g dissolved in distilled water A
pH over or under9.2 was adjusted byusing 12 M HCIor 2 M
NaOH, respectively. The final volume was madeup to 500 ml
C. I % NRS in PBS- Tween·20. NRS(Normal rabbit serum, Animal
Care, MUN) 1.0 ml and 100 III ofT ween detergent (R06435 -74,
BDH Chemical Co.)dissolvedin andmade up to 100 mlin PBS (pH
7.2)
D, I % NRSin carbonate - bicarbonate buffer(pH 9,2). NRS 1.0 ml
was mixedin 99 mlof carbonate- bicarbonate buffer
E, 0.15 M NaCL withO. I % Tween-20. Sodium chloride (ACS 783,
BOH lnc.}35,4 g and 4 ml of tween detergent were dissolved in 4
litres of disti1lcd water
(8) l'lat e reader (Bio-Tek Instruments Inc., Burlington, vermont)
5.2 Anll- e EA EUSA
5.Z(a) Materials
( I) CEA (supplied byOncology Research Laboratory), purified as detailed in
Ford et at, 1978b and dissolved in carbonate bicarbonatebuffer
(2) 11·285·14 anti-CEA monoclonal antibody (lgG1 positive control)
(3) Ag8 (P3X63Ag8; IgG. negative control. AmericanType Culture
Co llection, Rockville, Maryland)
(4) RAM·HRP (Rabbit anti-mouse immunoglobin horseradish peroxidase.
P 161. Dako, Denmark)
(5) ABTS (refer to section II 5,I(a)) .
(6) 1% NRS(Normal Rabbit Serum) in carbonate buffer, pH 9.2
(7) ELISA buffers(section II 5.I(a»
(8) HPLC fractionatedantibodies
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II S.2(b ) Mdhod
(I) 96 well ELISA plates were coaled with CEA ( 100 ~ I perwell at 2,5 ~g!ml), These
plates were incubated at 31'C for 3 hours. Then. the plates were stored at 4<'('
overnig ht
(2) The coating solut ion was removed and the plates were washed 6 times each with
0.15 M NaCVTween·20 solution using a wash bottle
(3) 200111of 1% NRS in ca rbonate buffer was added to each well as a blocking
solutio n and the plates were then incubated at 31'C for I hour
(4) Plates we re washed as before (step #2).
(5) The HPLC fractions were then added 10the test wells at 100}II per well
The anti-CEA ELISA contro ls were: backgroun d (1% NRS in PBSrrween.20)
positive control (11.285.1 4 Mab) at 10, 1. 0.1, & 0 ,01 ~g1ml in 1% NRS in
PBSrrween-20; negative control (Ag8) 10 J.I g1ml in 1% NRS in PRs rrwcen, The
controls were added in triplicate
(6) Plates were then incubated at 37°C for 3 hours.
(7) Plates were then washed as before (step #2)
(8) RAM-H RP was added at a 1:1000 dilution in 1% NRS pnSrrwcen-20 at 100 ~ I
per well
(9) Plates were then incubated at rrc for 3 hours
( 10) Plate s were was hed as before (step #2)
(11) ABTS solution was then added at 100 ~I per well and incubated at RT (in the
dark) fo r I hour.
(12) Plates wereread using a plate reader at a wavelengthof405 nm.
II 5.3 Anti - DOX ELISA
II 5.3(.) Mat erials
( 1) ELISA buffers(section II 5.I(a» .
(2) Doxorubicin(DaX ) at 2 ug/ml .
(J ) HPLC fractions of ascitic fluid
(4) RAM-HRP (section II 5.1(a»
(5) ARTS (refer to section II 5,l(a»
II 5.3(b ) Mtthod
The procedurewas similar to the anli-CEA ELISA with the following
exceptions, Thecoating antigen used was DOX (2 tJ.g/ml)and there was no positive
antibodyco ntrol. The controls were: background (1% NRSin PDSrrween-20);
negativecontrol ( AgSimmunoglobulins in PBSlTween-20).
II 5.4 Anli· DOX · USAELI SA
II 5.4( .) Matui,ls
( I) OOX-BSAconjugatc at 2 1lglmlofDOX (sectionII 4,0)
(2 ) 1% NRS inPBSrr ween-20 (pH 9.2)
(3 ) Negative control (AgSantibody)
(4) Materials in section 115.1(a).
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5.4(b) M ethod
Theprocedure was similar to theanti-DOXELISAwith theexceptionof using
OOX-BSAas the coatingantigen
5.5 And · USA ELISA
5.5(1l) Mllttrials
( \) Coatingwith BSAat the same concentration used in the DOX-RSA
conjugate(at 2 Ilglmlof DOX)
(2) Negativecontrol (Ag8antibody)
(3) 1% NRSin PBSfTween·20 (pH 9.2).
(4) Materials(sectionII 5. I(a».
S.S(b) Mtthod
The procedure was verysimilar to the anli-DOX-BSA ELISA with the
except ion that the coating antigen usedwas bovine serumalbumin(BSA)
5.6 DUlll Spedfidty ELISA
This procedure was similar to the other ELISA assays. Thc only dilTerences
were: the wcllswere coat edwith DOX-BSAat 2 1Jg/ml DOX (100IIIper well)and
CEA-HRPwas used( 1/100dilutionin 1% NRS/PBS/twecn) instead of RAM·HRP
AnELISAwasdonefirst to test the selectivity ofthe CEA-HRPconjugate for
theanti-CEA 11-285-14. Wellswere coated with5 I-lglmlof 11-285-14antibody or
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non-specificantibodyAg8 andblocked with I % NRSlPBSrrween-20. The conjugate
wasadded in qu adruplicate indoublingdilutions ( 1/5, 1110, 1120, 1/40, 1180, 1/ 160,
11320, 1/640, 1/1280, a nd 1/2,560)
6.0 MICRO CYTOSTASIS ASSAY
Theproc edure usedwas thai published by Ford et al (1989)with the
modifications indicated. This assay wasused to deter mine the sensitivity of the cell
linesto thedrug plusantibodyand drugalone. The MIT or tctrazolium salt (yellow
solution) reacted with succinate dehydrogenase to give a formazanprecipitate (purple
solid). Theprecipitate was dissolved in DMSO to give a purple solution before
absorbancereadingswere taken. Succinate dehydrogenaseis a functional mitochondrial
enzyme found onlyin the Jive or vieblecells. Theamount of forrnazan precipitate
formed in each wellcorrelateddirectlyto the level of functionalenzyme or the number
of live cellsin that well. Therefore, thetest sample absorbance readings were an
indication of cell survival, whencomparedto control absorbance levels.
6.0(a) Malrr ials
(I) SKCOI and COLO320 DM coloniccancer cell lines
(2) Multichannel digital micropipette- (NichiryoCo. , LTD. I, Kanda-
Matsunaga-choChiyoda-Ku,Tokyo,Japan)
(3) Sterile pipette lips(200 lJl) (leN FLOW S, ICN Biomedicals, Inc., Costa
Mesa. CA.)
(4) Linbro 96-well ( I x 0.7 em, 0.35 mlwellcapacity) flat bottomed tissue
culture plales (N76-003-05 FlowLabs)
(5) RPMI and MEM medium containing 10%fetal calf serumand 6 rnlof
glutamine
(6) SterilePBS
(7) MTT (3 [4,5Dimethylthiazol - 2 - yl]- 2,5 - diphenyltetrazcliumbromide)
(#M.2 128, Sigma ChemicalCo.)
(8) Clinical rotator (Fisher ScieraiticCo., New Jersey)
(9) Doxorubicin(Da X) (Adria Laboratories)
(10 ) Bispecific antibodiesor Ag8antibody
II 6.1 MicrOf:yloslasisAssay Method
The rollowing isan outline of the microcytostasis assay(MIT ) procedure used
in the OncologyResearch Laboratory. The 96 well plates usedin theassay had 12
columns of wellslabelled1-12 and 8 rows of wells labelled A-H.
( I) Cultured cellswere uv psinieed (section II 1.5) and counted (section II 1.6). [If
cellswas required per well ina 96 well plate at 100 IIIper well.
(2) 10 ml of'celtsat 10l cells I well ( IO~ 101al) gives 101 cellsper ml.Thesecellswere
plated and incubatedat 3'rC (5% COl) for 24 hours. Column 12, rows A·J-1 of'the
assay plate did not receive anycells.
(3) Medium wasthen carefullyauctioned from the wells using:a multichannel pipetter,
making sure not to distu rb the ce lls.
"
(4) Doxorubicin was dilutedinsterilePBSand Ihenadded 10the plate in quadruplicate
(rows A 10 0) in Jog dilutioll5(startingwith column I with 0.000001nglml lo column
II having 10000 ng/ml, respectively). Thesedilutions wereadded II 100 ~1 perwell.
(5) RowsE · H (columns I to J I) were controlsand received 100 J.l1 of medium. The
plate was then incubated al 3"fC in I humidifiedincubator (5% COJ)for 24 hours
(6) Both drug solutions and mediumwere then sectioned from the welts. Thiswas
followed by three washeswith sterilePBS (200 IJIPBSper well).
(7) Mediumwas thenadded 10each well(100 1.11per well)followedby a 24 hour
incubation in a rtc humidified incubator (5%COJ) .
(8) Mediumwas sucuoned from the wells 100 IJIof MTT solution(5 mglml stock
diluted I:10 in medium) wasadded10each well. The plate was then incubatedin I
humidified3'PCincubator for 4 hours
(9) TheMIT solulion was thensuctionedfrom each well OMSO wasadded(100
J.l1 per wdl) and the plate was placed on a shaker for 10minutes. Finaly,the
a~rbance of each well wasdeterminedwith . plate reader using dualwavelengths
of630.ndS70nm
(10) Data points wereenteredin a statistical computer program and the points were
fitted to a sigmoidcurve. The IC~ valuewasdetenn inedby inputtingY-SO,
corresponding to 500/.survival and then receiving the corresponding
concentration or X value.
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II 6.2 Selection ofAnti bodies for Testing
Each ofthe bispecificantibodiesweretested foranti-CEA. antl-Dux. anti-
DOX. BSA. anti·BSA and dual (anti-CEA. anti.DQX) activity, at first usingH pl.C
fractions from 100 fll injections. Thosesamples with thehighest anti-CEAand anti-
DOX activitywere selectedfor furtheranalysis, Out of those selected. the samples
with the largest volume andconcentration ofantibodicswere fina lly chosenfor
preparativeseparation, using a 5 ml manual sample injection loop, and withI ro[ IWLC
injections. These samples were testedagainusing ELISAand then all crthe remaining
sampleswere separated by using HPLCwith repealed 5 ml injections
II 6.3 Antibody-M t,dil lcd Targeting Meth od
Thisprocedure was very similar 10 the DOX IClO assay with the exceptionof
the followingsteps. This assaywas carriedout using theBSMabs and the nonspecific
AgSantibody in various concentrations withSKCOI andCOLO 320 DMcell lines
Thechangesto the microcyrostasieassay procedure in section II(;.1 occur in
step #4. After the mediumis removed,the antibody (BSMab or Ag8) was diluted in
medium at 10, 1, 0.1. and 0.01 ~glmJ. The 10~glml dilution wasadded to columns I-
S (rows A-D), I ~g!ml to columns 6·10(rowsA·D), 0,1 Ilgl mlto co lumns1· 5 (rows
E.H). and 0.01 ~g!ml lo columns 6--10(rows E-H), Columns 115 and #10served as
antibody control wells for each antibodydilution. The remaining 4 columns of 4 wells
for each dilution were used as test wells. Column II wasthe PBSco ntrolwhile column
12 was a blank. Theantibodieswereincubated for 15 minutes at41lC.
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Thesupernatantwas thenremovedand thedrug dilutions wereadded Dilutions
wereaddedfrom the lowest 10 the highestconcentrations inco lumns I to 4 and
columns 6 10 9, respectively. The 8 wellsof eachcolumnreceived 100).lJofthe
assigned drug dilution, The dilutions used for theSKCOI cdlline were 1000, 100, 10
and I nglmlwhile theCOLOno DMdilutionswere 10,000, 1000, 100 and10 nB/mI.
These d ilutions were made according to the Ie ",values foreach cellline. Theplates
wert then incubated a137°C for24 hoursand theprocedure co ntinued as insection II
6.1(sl ep Il8)
Al thesame lime, a second plate was setup using DOX aloneat the same
dilutions. This plate served asa DOX control plate.
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CHAPTER 111
RESULTS
III 1.0 PRODUCTION OF DOX-B SACONJUGAT E
DOX·BSA conjugate was required ASone of the coating reagents for the errtl-
DOX·BSA ELISA,aswell as for the dual assay. Three conjugates were preparedlind
purifiedusingSephadex0 -25 chromatography. Two-mlfractionswere collected at 5
minute intervals andspectrophotometric readings takenfor each fraction. The first
sample (Figure 2) hadII DOX:BSA ratio of 1.66. The secondsample readings showed
avery similar levelof conjugation witha DOX:BSA ratio of 1.83 (Figure 3)
Approximately 4 mlwas retrieved fromthe first experiment and 4 ml fromthe second.
There wassome precipitation of the DOX during these experimentsbut thiswas kept
toa minimum by adding the drug slowlyand maintaining veryslow stirring
Athird conjugation was performed andthe DOX:BSA ratio was calculatedas
1 15 (Figure4). Thiswas performed without theovernight incubation and resulted ina
clear product with no precipitation. There was more consistent slowstirringusing a
very smallmagnet which may have accounted for the better product. Fraction #9 also
had a highreading for DOX with a DOX:BSAratio of 20.8.
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Figure 2. DOX· BSA conjuga te purification #1. Co njugate sepa ration was performe d
using a Sephadcx 0·25 gel filtrationcolumn. 5 minute fractionswerecollected and
analysed spcc trop botcm ctrically at 450 lind 280 nm
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Figure 3 DOX-BSAconjugale purification 112. Procedureswere carriedoul as in
Figure 2.
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Figure4. DOX·BSAconjugate purification#3. Fractionswerecollectedfroma
Sephadexgel column at 5 minute intervals. The legend isthe sameas for Figure2.
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III Z.O PRODUCTIONO F CEA-HRP CONJUGATE
CEA-HRPwas the reagent required in the dualassay, replacing the
RAM-HRPused in the other ELiSAs. This procedure was developedby Reddy,
(1993); Reddy& Ford, (1993)for thisparticular purpose
All the HRPin solution appeared to haveconjugated to eEA (Figure5) as
HRP was only detected at the same peak as the eEA peak at 280om. In order to
demonstratethatthis conjugate wasfunctional, a selectivityELISA was done using the
anti-eEA 11-285-14 Mab(Materialsand Methods section II 5.6). Once the ABTS
substrate was added the conjugate showed highlevelsof HRP activity(Figure 6)
There was high activity up 10 1180dilution of the pooled fractionswhen tested against
the anti·CEA 11-285- 14 antibody. Thecontrol (nonspecific)antibodyresulted in very
low HRP activity for all dilutions ofthe conjugate. This result demonstrated the activity
and specificity of the conjugate for anti-CEA antibody
III 3.0 ASCITI C FLUID PRODUCTION AND PP ~)TEIN A COLUMN
PURIFICATION
Ascitic fluid was obtained by injecting the growing BSMab producing
hybridomas intraperitoneaJly into Balb/c mice (Materialsand Methods section 2.0)
Varying amounts of ascitic fluid were collected for each hybrid (Table J), This
depended on how much ascitic fluidwas produced by each mouse and how long the
mouse lived to lap the fluidfrom it.
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Figure 5 CEA·HRP conjugate purification. The separation was performed using a
Sephadex Q·75 gel filtrationcolumn.Fractionswere collectedat 2 minute intervals at a
rate of 0.75 rnl/rninute. Fractions were spectrophotomelrically analysed al403 and 280
nm
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Figure 6. CEA·HRP conjugatespecificityand sensitivityELISA results. ELISA plates
were coated with 5 ~glml of test antibody ( 1 1~285 · 14, anti·eEA) or control antibody
(AgS, non-specific). Conjugate was added in doubling dilutions from liS to [/2560
Table I.Summery of Ascitic Fluid Collection and Protein A Purification.
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Bisp~cific: Pooled Protein A Protein# Anim als UnpurifiedJlybridoma Inoculated Asdtic Fluid Purified Aseilk Concentration
number
ml F1uid(ml) (mglml)
26-6IR I 20 85 16.5 2.52
26-6 1-4 I I 58 9 1.78
26-6 1-10 17 50 20 5 2,04
57- 11-25- 17 14 120 17.5 2.36
26-6 1-2 II 62 5 2.16
26-7-35 20 J9 6.5 0.55
57-9.6-4 II 45 6.0 2,07
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Onceprotein A purified, the ascitic fluid samples were concentrated (Table I)
Some sampleshad higher proteinconcentration than others and eachditteredin the
final volume availablefor furtheranalysis.
III 4.0 " PLC STANDARDIZATION
In order to begin the HPLC separation of the seven bispecific monoclonal
antibodies, the procedure hadto bestandardized first. Fifty microfitres or eachprotein
A purifiedantibody was separatedusinga 60 mMto 180 mMphosphatebuller
gradient (Xiang et al, 1992). This was undertaken in order to determine how each
antibody would separate underthese conditions
III 4.1 Standa rdization Using Paren tal 11-285-1 J (llI nti·CEA monod onal
antibody IgG,)
III 4.1(11) HPLC Sepa rat ion
Fifty microlitres (2.50 mglml) cf the protein A purifiedparental monoclonal
antibody was loaded onto the HPLC column. The elution look placeover a 60 minute
period fromtime 20to 80 minutes as seen in Figure 7, usinga60 mM10 180mM
buffergradient. The first peak,seen at approximately4 minutes, is a small loadingpeak
whichis an artifact of all HPLC separationprocedures. There is a major peak which
starts at approximately 58 minutes and endsat 65 minutes. Both peaks were collected
manually andanalyzed by ELISA for anti·CEA activity.
a,,
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Figure 7. HPLC separation of monoclonal 11-285-14 . 50 ...1ofa 2.5 mglml sample
was loaded onto a hydroxylapatite columnand eluted using a 60 mM 10180 mM
phosphate buffer gradient. The absorbance of the eluatewas analysed81280 nmand
fractionscollected at 1 minuteintervals.
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III 4.I(b) ELISA Results
The anti-CEA ELISA results revealed that peak I containedvery little anti-CEA
activity (Figure 8). The resultingabsorbance reading was very similar to that or thc
control wells.The control mean absorbance plus 2 standard deviations was OJ21. I'eak
2 gave II very highanti-CEAactivity. The absorbance reading was double that found
for the 10and I J.lg/ml dilutions of the positive test control. The positive test control in
this case wasthe unfrectioned 11-285-14 parentalmonoclonal antibody.
III 4.2 Standardization of DSMab Separatio ns
Onlyone of the bispecffic antibodieswas used for this initial standardization.
The 26-61-2 antibody was chosen for thisprocedure
III 4.2(a) HPLC Results
The SOJ.l1sample revealed6 distinct peaks (Figure 9(a» witha small shoulder
between peaks 5 and 6. Peak 6 showedan elution time very similar 10that of peak 2 of
Figure7, Therewere no more protein peaks following the set time period shown in
Figure 9(a) where the absorbance reading returned to baseline(results not shown)
Each of the peaks was collected manuallyinto 10mJtubes. The volumes collected in
the tubes varied from peak to pcak as each peak varied in overall size. This manual
col1ecting didresult in peak overlapin each lube as the tubes were changed only when
a "new" peak started to elute.
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Figure 8. Anti-CEA ELISAresults of 11·285·14 HPLC purified peaks, Peakfractions
weretested usingCEAcoaled ELISA plates and a 1/1000 dilution ofRAM·HRP.
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Figure9(a), HPLC separation of ascitic fluidcontaining26-61-2 bispecificantibody
50 ",I of a 2.0 mg/ml sample was loaded onto a hydroxylapatite column andeluted
using a 60 mM to 180 mM phosphate buffergradient.Eluate wasanalysed at 280 nm
andcollectedat 1 minute intervalswith a flowrete of I mVminute.
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III 4.1(b) ELISA Results
Therewere four ELISA'sperformed on the initial HPLC separation. Thesetests
includedanti-CEA,anti-DOX, anti-DOX-BSAand anli-BSA. The anti-CEA results
(Figure 9(b» revealed no activity in peak I, as in the anti·CEA result of peak I with the
parental 11·285- 14 (Figure 8). Peaks 2 throughto 6 did show increasing anti-CEA
activity. Peak 6 showed the highest anti-CEAactivity similar to that seen with peak 2
of the parental 11-285-14 (Figure 8)
Thehighest anti-DOX activitywas found in peak 2 with an absorbance reading
of 1.462, The level of activity decreased from peak 2 through to peak 6 with peak 6
having the lowest level.
The anti-DOX-BSA ELISA results (Figure9{b» were very similar to those of
the anli·DOXELISA. The highest absorbancereading was in peak 2. Thelevel of
absorbancedecreased from peak 2 to peak 6. The intensity of the readings were not as
high as for the anti-DOX ELISA.
The an ti~BSA ELISA(Figure 9(b» did not givethe samepattern of absorbance
readingsas did the anti-DOXand the anti·DOX-BSAELiSAs. Peaks 1and 6 gave
very low readings while peaks 4 and 5 gave the highest levels.
III 4.3 HPLC Procedurt Modificalions
A60 mMto 360 mMgradient was tried with the same conditions (Xiang et ai,
1992) inan attempt to try and improve the separation. Upon viewing these differences
(Figure 10)it was decided 10 proceedwith the 60 mM- 360 mMgradient due to its
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Figure 9(b). ELISA results of26-61-2 HPLC separation peaks Anli-CEA. anti-Dux.
anti·DOX·BSA and anli-BSA ELlSA's were performed oneach peakfractio- using
100 III of sample anda 1:1000 dilution of RAM·HRP
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Figure 10. A comparison of two HPLC gradient profiles. The solid line (_) illustrales
a 60· 180mM phosphate buffer (PB)gradientelution profileof a so IIIinjection or26-
61-4 ascitic fluid. The dashed lineCo- 0) illustrates the same volumeof sampleeluted
with a 60-360 mM PB gradient.
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better discrimination of peak areas
Due to the inconsistencies of collecting the fractions manually, a FRAC~1 00
fraction collector was programmedto collect thesefractions at I minute intervals. The
lube numbers thencorresponded to each minute of the timescale on the x axisof the
I-IPLC profile This permitted a more preciseanalysisof each peak.
III 5.0 ANALYTIC AL.IIPLC AND ELISA ANALYSIS OF ALL SEVEN
IfYDRIDOMAS
rOTthis procedure I ml of each bispeciflcmonoclonalantibodywas loaded onto
the column and fractions collected. Thiswas performed using the 60 to 360 mM
phosphate buffergradient protocol. Each fraction was analysed for anti-CEA, anti-
DOX, anli-DOX-BSA and anti-BSA activity.
III 5.1 Bispetilic Monoclonal Antibody 26-61-1
III 5.1(11) IIPLC Profile
The I ml HPLC profileof 26-61. ] ilIustrntest wo major peaks (Figure I I). The
first peakstarts at approximately 12 minutes as a sharp peak and tails out between IS
and 28 minutes. The second peak region starts at approximately 50 minutes and ends at
approximately 65 minutes. This region contains two distinct peaks (54 and 57 minutes,
respectively) with a shoulder at 53 minutes, just before the fit'st peak in that region.
Pe ak 1
A,o,' ,
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Figure 11. HPLC separationof asciticfluid containing 26-61- ' blspecincantibody. A
1mlsample was loaded on to a hydroxylapatite columnand eluted using a 60 mMto
360 roM phosphate buffergradient. Theeluate was analysedat 280 omand fractions
werecollected at 1minute intervals
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III 5.1(b) ELISA Results
ELISA resultsof the 26-61 -1 HPLC separated fractions showed high ant i-DOX
and anti·DOX·BSA activity clustered between 10 and 20 minutesand between 48 and
65 minutes(Figure 12). The anti-DOX-BSA was highest in the 50 to 65 minuteregion.
Anti-CEAresults started 10increase at approximately 10 minutes and reached a
maximum at 50 minutes, stabilisedup to 65 minutes and decreased down to near
baseline at 70 minutes. The anti-GSAactivity of this hybridomawas low in all the
fractions. There was one area of activity between 50 and 58 minutes but the absorbance
was not higher than0.25 om
III :!i.2 Dispc('ilic Monodon al Antibody 26-61-2
III :!i.2(,.) "PLC Profile
The HPLC profileof the 26-61-2 asciticfluid (Figure 13)indicates two major
peak regions, The first eluted at approximately8 minutes with a flat plateau region
between 17 and 37 minutes, The second peak region contained three discrete peaks
each eluting at 41, 45 and 52 minutes, respectively. The absorbance level did nol return
10 0 followingthis last peak but rather it remained at a very low level for the last 40
minutes
III 5.2(b) ELISA Results
The ELISA results (Figure 14) indicatehigh anti·DOX·BSA activity in the first
peak region with decreasing levels in the between the two major peak regions. There is
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Figure 12. ELISAresults ora 1 m126·6 1-1 HPLC separation. I minute fractionswere
tested foranti-CEA, anti·DOX, anli·DOX·BSA andanti-BSA activity Tha absorbance
was readat 405 nm.
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Figure 13. HPLC absorbance profileof ascitic fluidcontaining 26-61-2 bispecific
antibody. A I 011 samplewas loaded and eluted from a hydroxylapatite column using a
60 mMto 360 mM phosphate buffer gradient. Absorbance was read at 280 nmand I
minute fractions were collected
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Figure 14. ELISA resu lts of a I ml 26·61 ·2 HPLC separation. Fraction s were tested for
anti·CEA, anti·DOX, anli·DOX ·BSA and anli~8SA activity. The abso rbance was read
at 405 nm.
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also an increase in activity at approximately60 minutes and then a decrease in optical
density10 baseline level
The anti-CEA activityincreased at approximately 14minutes. returned to near
baseline levelsand increased again at 34 minutes. The anli-CEA activity was much
greater at 56 minutes. reflected by an absorbance oro. 80, The optical density decreased
very quickly after this point bUIdid not go below 0.2 for the remainder of the fractions
The anti·DOX results for the 26-61-2 purifiedascitic fluid did nor show any
majorpeaks throughout theentire gradient. Therewas an increase in anti-BSA activity
at approximately 18 minutes into the HPLC separation. Levels then returned to baseline
unlit fraction #59. Here theoptical density increased to nearly 0.2 and then returned to
baselinefor the remainderof'the fractions
III 5.3 Bispedli( Monoclonal Antibody 26·61·4
111 5.3(8) IIPLC Profile
This I mlsample separated intoa sharp peak at approximately 9 minutes anda
broader peak areaat approximately63 minutes (Figure 15). The first peak started
elutingat 7 minutesand ended at 11 minutes. After this point. a broad shoulder and a
low plateau region appearedfrom 12 minutes up to approximately 4J minutes. The
second peak area started to elute very slowly at approximately 48 to 59 minutes. Then
the amount of elutingprotein increasedvery rapidly at approximately 60 minutes to
give lWO peaks al 64 and 67 minutes. The absorbance levelthen decreased rapidly 10
give another low shoulder region from approximately 69 to 80 minutes.
,.,
Peak 1
Figure 1S. HPLC absorbance profile of ascitic fluidcontaining26-61-4 blspccific
antibody. A I mJsample was loaded and eluted froma hydroxylapatite column using a
60 mM to 360 mMphosphate buffer gradient. Fractions were collected at I minute
intervals and absorbance read at 280 nm
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III 5.J(b) ELISA Results
The anti-CEAactivityof these fractions (Figure 16)followeda different pattern
to thai of the other hybridoma fractions. The activityincreasedrapidlyat approximately
8 minutes and stabiliseduntil 4Sminutes. Then the opticaldensity levelled for 9
minutes before it increased veryrapidly again. This timeit stabilisedfrom 59 minutes
until 86 minutes and then dropped back 10background level The anti·BSA and anti-
DOX-BSA activity peaked between8 and 12 minutes at approximately the same level.
Both activitiesthen stabilised from12 1042 minutesbefore returningto background
activitylevels. Both activities again increased at 58 minutes and slowlydecreased from
66 1080 minutes. The anti-OOXactivity was not as great as that of the ant-BSA and
anti-DOX-BSAtest results. Thepattern of activitywas similar to that of the previously
mentioned results but with much lower activitybetween 8 and 12 minutes. From 13 to
60 minutes there was only background activityand no plateau as observed previously
for the anti-DOX andanti-DOX·BSA tests. The level of anti-DOXactivity then
increased at 60 minutes and followeda similar pattern to that of the anti-BSA results.
III 5.4 DiJpetifk Monoclonal Antibod y 26-61-10
III 5.4(1) HPLC Profil e
There were two distinct peak areas withinthe HPLC profileof the bispecific
monoclonalantibody26-6 1-10(Figure 17). The first peak appeared at 8 minutes into
the elution procedure and ended at 20 minutes with a slight tail effect.There was then a
plateau region from 20 minutes 10 45 minutes. A shoulder (peak 2) appeared between
o anti -OOX-BSA
D anti-OOX
6 anti-BSA
o anti-CEA
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Figure 16. ELISA results ora 1 mI26·61-4 HPLC separation, Fractions weretested for
anti·CEA, anti·DOX, anti-DOX·BSAand anti-BSA activity. The absorbancewas read
at 405 om.
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Figure 17. HPLC absorbanceprofile of ascitic fluid containing 26-61-10 bispecific
antibody. A I mlsample was loaded and eluted from a hydroxylapatite columnusinga
60 mM 10 360 mM phosphate butfer gradient.Fractions were collectedat I minute
intervals and absorbance read at 280 om.
51and 53 minutes and the third peakat 54 minutes. The fourth peak of the profile
appeared at 58 minutes and finished at approximately 62 minutes
III 5.4(b) ELISA Results
The 26-61-10anti-CEA results, as with most of the nSMab's, showeda
gradualincrease in opticaldensity with time (Figure 18). This activity reacheda
maximum le....e1at approximatelythe 50 minutes fraction where it stabilized for il 20
minute period and then decreasedvery quickly. At the 76 minute period, the activity
had dropped back to background level
The anti-BSA activity was veryhigh within the first peak regionbetween 9 10
14 minutes(Figure 18). The activitydecreased after this point but did not drop below
an absorbance0(0 ,75. The activity fluctuated withinthe 14and 46 minute fractions
and increased again at the 47 minute fraction. The levelof activity again fluctuated until
the 62 minute fractionat which pointthe anti-BSA activity quickly dropped down to
backgroundlevel. The activity did not change after this point
The anti-DOX-BSA activityof this HPLC separation first showedan increase in
activityat approximatelythe 8th fraction (Figure 18) which was withinthe first peak
regionoCthe HPLC prolile (Figure 17). Theactivity level thenslowlydecreased until
the 40 minute period. The absorbance increased over a 10 minute timespan but did not
increase much beyond 0.5. After this point the absorbance dropped to approximately
0,25 and slowly returned to the background level thereafter.
The anti-DOX activity was the greatest within the first peak region of the
89
2 .0
o a nti-DOX-BSA
a anti-DOX
01 a nti-BSA
1.5 o anti-CEA
w
0
z
-c
"'
1. 0
'"0VI
"'<
0.5
100
Figure 18. ELISA results ora 1 mI 26-61-I OHPLC separation. Fractio ns were tested
toranti·rEA , anti·DOX. anfi·DOX·BSAand anti·BSAactivity. The absorbancewas
rcad al 40S nm
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HPLC separation with a peak leveljust beyond 0.5. The activitylevel thendecreased
after this point and did nol increase any more. slowlydecreasing 10a backgroundlevel
threughou t tbe remainder of the fractions
I II 5.5 Bisprtifi c !\Ion odona l Antibo dy 26-7-35
III 5.5(8) HPL.C Profile
The HPLC profile of this hybridoma, like the other hybridornas. gave two majm
peak regions {Figure 19). The first eluted between 5 and 15 minutes while the second
eluted between 35 and 65 minutes The second peak region contained two distinct
peaks whichreached maximum absorbance levels at 44 and 54 minutes. respectively.
Following the second pc,'k region the absorbance remained flal but did net return 10
the referencelevel (0 )
III 5.5(b) ELISA Rrsults
The anti-CEA activity of the 26-7-35 hybridoma was verysimilar 10 that of the
\>.:Ier hybrids where it increased slowly over the first half ofthc IIPLC separation
(Figure 20). Thelevel of activity reached a maximumover the second peak region, in
this case between the 35 and 72 minute fractions. Ilowever, the major portion of the
second peak region was eluted bythe 60 minute fraction with a tail portion that
extended to approximately the 75 minute fraction
The anti·BSA activity was high within the two peak regions of the IIPLC
profile (Figure 20) with peak values occurring in the 7 and 49 minute fractions.
I'Cilk 1
Pe ak 2
Pe ak 3
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Figure 19. HPLC absorbance profile of ascitic fluid containing 26· 7·35 bispecific
antibody. A I ml sample was loadedand eluted from a hydroxylapatjte column using a
60 mM to 360 mM phosphate buffer gradient. Fractions were collected at 1minute
intervals and absorbanceread at 280 nm
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Figure20. ELISA results ora! mI26-7-J5 HPLC separation. Fractions weretested for
anti-CEA. anti-DOX,antj·DOX·BSA andanti·BSA activity. The absorbancewas read
al 405 nm.
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respectively
Anli-DOX-OSA assay(Figure20) gavetwo pointsof highactivity in the first
peak rtgionof theHPLC separation profile(Figure 19). This activityoccurred in the 7
and 12 minute fractions, respectively. This activity thendecreasedand remained at•
b.1ckgroundlevelthroughout the remainder or the fractions.
Theanli·DOX activity in thishybridomawas not verystrong for most offh e
fractions(Figure 20), The only real indicationof activity occurred in the firstpeak
region in fraction number 6.
III 5.6 Bispt dfi c Monoclonal Anti body 57· 11·15-17
III 5.6(. ) HPLC Prolile
The57· 11·25· 17 protein A purified ascitic fluid also separated inlo two major
peak areas(Figure 21)_Thefirst peakwas wry sharp andoccurred between8 and I)
minutes.The second peak region contained two peaks. Thefirst was at approximately
S4minutes and the second at approximately 56 minutes. The peak regionspannedthe
SO10 60 minute limeperiodwith a low tail region that reached baselineabsorbanceat
approximately 80 minutes, The absorbance between the two peak regions did not
return to baseline, but rather it showeda low plateau pattern.
III 5.6(b) ELISA Results
This BSMab showed very highanti-BSA (Figure22) activity in both peak
regions of the HPLCprofile (Figure 21). The anti-DOXand the anti-DOX-BSA
9 4
Tln,.. (...ln ,"~.'
Figure 21. HPLC absorbanceprofileof ascitic fluidcontaining57-11·25-17 bispecific
antibody. A J mlsample was loaded and eluted from a hydroxylapatite column using a
60 mM to 360 mM phosphate buffergradient. Fractions were collectedat I minute
intervals and absorbanceread at 280 nm
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Figure 22. ELISAresults ofa I mI57-1 1-25-17 HPLCseparation. Fractionswere
tested for anti-CEA, anli·DOX, anti·DOX·BSAand anti-BSAactivity. Theabsorbance
was readat 405 nm.
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readings weremuchlowe r withthe highestlevels occurringin the twopeak regions
Theanti-CEAresults, on theother hand, were highfromthe 10 minute fractionup 10
Ihe BO minutefraction
III 5.7 Bispetific Monod onal An tibody 57-9-6-4
III 5.7(a) HPLC Profile
The HPLC profile ofthe 57-9 -6-4 I ml sample separation was different fro m
that of the othe r hybridomas (Figure 23). As withthe other samples, there was a major
peakregionat approximately9 minutesbut thesecondpeakregiongave verylow
absorbancereadings. There wasan indicationora secondpeak between37 and56
minutes ofthe separation .
III 5.?(b) ELISA Resulls
There were positi ve ELISA results from the 57·9-6·4 HPLC separation a nd
theywe reno lowerthan the26-7-35 ELISA results (Figure24). Theanti-CEAELISA
results gavea verysimilar patternof activity to that of theother hybridomas whereby
theactivitybeganto increasewithin tbefirst peakregionand continued to plateau over
thesecondpeak region. Theactivity remained high beyondthe second peakregion and
quickly decreasedtobackground levelsafter the74th fraction.
Theanti-BSAactivitywas highwithinthe two peakregions of theHPLC
separation. The firsthigh activitypeakoccurred at 9 minutes and the secondbetween
39and 48 minutes(Figure 24).
9 7
Pc ak ],
T~n~ (m in....,. )
Figure 23. HPLC absorbanceprofile of ascitic fluidcontaining57-9-6-4 bispecilic
antibody. A I ml sample was loaded and eluted froma hydroxylapatitecolumn using a
60 mM to 360 mM phosphate butTer gradient. Fractionswerecollected at I minute
intervals andabsorbanceread at 280 nm.
98
.8
o anti -DOX-BSA
.7 D anti-OOX
• anti-BSA
.6 o anti-CEA
'" .50z
-c
CD
.40:
0
VI
.3CD
-c
.2
. 1
Figure 24 . ELISA results of a I mI57-9-6-4 HPLC separation. Fractions were tested
for anli-CEA, anti.DOX, anti-DOX-BSAand ami·g SA activity. The absorbancewas
read at 405 nm
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The anti-DOX-BSAandanti-OOXact ivity was verylow for this particular
hybridoma (Figure 24). Both tests showedhigh activity in the 9 mimte fraction but
remained verylow throughout the other fractions
III 6.0 DUAL ACTIVITY TEST
The presenceof dual activity was tesred in dilutions of the original protein A
ascitic fluid samples. The results in Table 2 indicate thai not all the samples responded
strongly in the test. The strongest reaction came from the protein Aconcentrated
sample of2 6-61- 10. Next to this were the 26- 7·35 and the 57- 11·25·17 results. 57-9-
6-4 gave the lowest response. The values obta inedfor thisparticular hybridoma were
not grea ter than the control mean plus two standard deviations (0.0647), therefo re.
theywere notconsideredto besignificant. The results with 26-61-1.26-61-2 and 26-
61-4 were signiflcant but $l:ill gave low readings
The protein Awashes, which wereco llectedfor eachof the hybrids.were also
checked for dual activity. This waschecked for possible lou ofvaJuableprotein in the
initial washing of the protein Acolumn. Results indicated verylow activity. Allbut the
26-61- 1 wash had values that were not significant (results not shown),
III 7.0 PREPARATIVE HPLC PURI FICATI ON
T o beable to scale up the purification of each of the bispecific antibodies a S ml
loading loop was used. This was required in order to load larger amounts of protein A
purified ascitic fluid onto the HPLC column. Theprocess required less timeand
Table 2. Results ofdual assayson hybridoma prote in Apurifiedascitic fluids.
100
A BSORBANCE R EADI NGS ~
8SMab
HYBRID # SAMPL E CONCENTRATION
STOC K tiS 1110 1/20 . /41l
16-61- 1 0.081 0.075 0.07 1 0.067 0 ,067
26-61-2 0.071 0.056 0.063 0,057 0 ,056
26-61-4 0.068 0.069 0.058 0,054 0:054
16-61410 0,169 0,120 0.089 0.OS3 0.053
26-7-35 0 103 0 .094 0.07 1 0.061 0 .062
57-11-25- 17 0,107 0.098 0.089 0.080 0 ,071
57-9-6-4 0.061 0.064 0.067 0.054 0 ,054
• Tests performed on doublingdilutions
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resulted in largerconcentrations of antibody per fraction.
Four of the originalseven hybridoma sampleswere selected for the final
analysis. This selection wasbased on the following criteria. First, each required a
significant resu lt from thedual assayELISA (> control mean +/·2 S,D.). Second. there
was a requirementfor a significant volume of proteinA purifiedsample. A large initial
volume meant that there was mOTC antibody available10work with in caseproblems
did arisefurther into the project Thirdly, there was a requirement for a reasonable
concentratio n of protein ineach protein A purified ascitic fluidsample. Fourthly, the
sampleshad 10 havepositiveELISA results forant i·CEA. anti·DOX, anti-DOX-BSA.
It was preferred that ift here was anyanti-8SA activitythat itwould be equal to
background absorbance orno greater than that of the anti·DOX·BSA results:
In order to conservereagents, and based on theanalyticalresults,ELISA
testing wasconcentrated on fractions from the second majo r peak area from the HPLC
separation. Also, becauseonly 5 rnl could beseparated at a timeand samples fromeach
of the secreted hybridomas consisted of 9 or more mI, several injections had to be
done, Therefore, each hybridoma had several HPLC profiles andas manysets of
fractions to be analysed
II I 7.1 26-6I- 15ml nPLCStparat ion
III 7.I(a) HPLC Profiles
There were three Sml injeclions of thishybridoma. Figures 25,26 & 27
illustrate how the prote inpeaks eluted at approximatelyth e sametime andgave very
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Figure25. First quantitative HPLCabsorbance profileof ascitic fluidcontaining 26-61·
1bispecificantibody. A 5 ml samplewasloaded and eluted from a hydroxylapatite
columnusinga 60 roMto 360 mM phosphatebuffergradient . Fractions werecollected
at I minute intervals and absorbancereadat 280 nm.
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Figure 26 Second quantitative HPLCabsorbanceprofile of ascitic fluid containing 26-
61-1 bispeciticantibody. Rest of details as for legend to Figure 25
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Figure 27. Third quantitativeHPLC absorbance profife of asciticfluidcontaining26·
61-1 bispecificantibody. Rest of details as for legend10fig ure 25.
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similar absorbance values
III 7.I (b) ELISA Results
The ELISAresults (Tables 3, 4 & 5) of the first, second and third separations,
respectively, all illustrate high levels of anti-CEAactivity. The anti-DOX and anti-
DOX·BS A activity levels sta rt off lower than the anti-CEA activity with a peak region
in the middle fractions. However, the dual assay results (Tables 3,4 & 5) reveal that the
dual responseof'this hybrirJoma was low. Fraction # 43 was the only fraction of the
first separation that had an absorbancereading greater than 0.076 (control mean +/~ 2
standard deviations)
III 7.1 26-61-45 ml HPLC Separation
III 7.2(a) IIPLC Proliles
The HPLCprofilesof the two 5 ml separations (Figures28, 29) illustrate the
sameelution timesfor the two peak regions. However, therewas a slight differencein
the appearance of the second peak region which was the area of interest for ELISA
screening
III 7.2(b) EUSA Results
The assayresults for the collected fractions (Tables 6 & 7) revealed that the
anti·CEA results were verysimilar however the antt-Dox and anti·DOX·BSA results
were a liuledifferent. The two assaysgave peaks in approximately the same fractions
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Table 3. ELISAresults from the first 5 ml HPLC separationof the 26·6 1· 1bispeciflc
hybridoma.
26-61- 1
FRACTION N
1st 5 ml SepaTRllon
ANTI ·C EA" ANTI·DOX"· ANTI·DOX· DUAL ASSAY
08A....- .. ....
40 1.276 0.198 0.379 0.060
41 1.296 0.364 0,291 0.066
., 1.049 0.232 0.447 0,071
43 1.224 0.349 0,504 0,084
44 1.294 0.457 0.764 0.062
45 1.296 0,643 0.790 0.07 1
4. 1.299 0,767 0.977 0.056
47 1.288 0.773 0.845 0.057
4' 1.301 0.943 0.800
4' 1.248 0,736 0.845 0059
50 1.209 0.626 1.013 0,063
51 1.274 0.650 1.082 0.06 \
52 1.224 0.564 0.7SI 0.060
53 U SI 0.668 0.622
54 1.133 0.566 0.759
55 \ .221 0.4 19 0.585 0.050
56 1.215 0.326 0,48 1 0,057
57 I .JIl2 0.334 0.330
Control Mean + 2 S.D.: ' 0.1440 •• 0 .0780 .., 0. 1538 .... 00760
Table 4. ELISA results from the second 5 ml HPLC separation of the 26-61-1
bispecific hybridoma
107
26· 61-1
I"RACT ION #
2nd 5 ml Sepa ra tion
ANTI·CE A" ANTI·DOX .... ANTI-DOX- DUAL ASSAY
BSA""" .. ......
4. 1.088 0.2 14 OA01 0.066
41 0.9S7 0.260 0.447 0.06 1
42 0.973 0.383 0,519 0.063
43 0,929 0.491 0.636 0.051
44 0,912 0,488 0.654 0.055
45 0.869 0.656 0.866 0.060
4. 0.997 0,643 0.775 0.060
47 0.969 0.658 0.850
4. 0.984 0.593 1.057
49 0 .897 0.609 0.891 0,054
50 0.703 0.718 0.669 0.058
51 0.639 0.574 0.566 0.065
52 0.922 0,622 0.742 0.059
53 1.0S3 0,631 0,497
54 1,077 0.594 0,736 0.051
55 1.035 0.406 0.425 0.053
56 0,967 0.327 0,454 0,048
57 0.710 0.289 0.757 0.057
Control Mean + 2 S,D.: · 0.1440 .. 0.0780 · ·· 0.1340 .. · · 0.0760
l OB
Table 5. ELI SA results from the lhird 5 ml HPLC separation of thc 26-6 1-1 btspecilic
hybridoma
16-61 - 1
3rd 5 ml Sfop.ulion
FRA CTION ti
ANTI-e EA- ANTI- DOX" ANTI-DO X- DlIALASSAV
BSA· ..• ... ...
4. 0.970 0, 110 0.361 0.047
4 ' 1.042 0,204 04 80 0.050
42 \ .02 1 0,34 1 0.842 0.050
43 1.091 0.396 0,55 7 0.047
44 1.036 0.47 1 0.693 0.049
45 1.070 0.535 0.660 00%
46 1.06 5 0.620 0.67 1 0,052
"
0,894 0.628 0.765 0064
48 0.999 0.6 10 0.706 0.052
4. 1.059 0,689 0.726 0(6)
50 1.095 0.819 0.912 0.0 54
51 1.102 0.603 0.823 0 ,069
52 1.138 0.647 0 652 0055
53 1.090 0.591 0.7 14 0,0 58
54 1.041 0.517 0.475 0,05 1
55 1.027 0.410 0 ,564 0050
56 1 035 0.400 0.4 19 O,1l55
"
1.039 0.391 0,79 1 0 0 56
Control Mean+ 2 S.D.: · 0 1440 · · 0,0780 "· 0.1340 .... 0.0760
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Figure 28, First quantitative HPLC absorbance profileof ascitic fluidcontaining26-61-
4 bispecificantibody. A 5 ml sample was loadedand eluted froma hydroxylapatite
column using a 60 mMto 360 mM phosphate buffergradient. Fractions were collected
at I minuteintervals and absorbance read at 280 om.
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Figure29. Second quantitative HPLC absorbance profileof asciticfluid containing26-
61-4 bispecific antibody. Rest of details as for legend 10 Figure 28
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Table 6 ELISAresultsfromthe first 5 ml HPLC separationof the 26-6-4 bispeciflc
hybridoma
26--61·4
FRA CT ION #
1st 5 ml Separat ion
ANTI-CEA ~ ANT I-OOX·" AN TI-O OX - DUAL ASSAYUSA...... .....
3. 0,966 0.20] 0.205 0,048
37 1.009 0.174 0.204 0.047
38 1.072 0,235 0.201 0,049
39 \.090 OAt8 0.218 0.058
40 0.971 0,800 0.356 0,048
41 1.0] 5 1.099 0,375 0.047
42 0.984 1.389 0.666 0,063
43 0,936 1.586 0,761 0.061
44 0.991 1.609 0,603 0,049
45 1.032 1.550 0,659 0 .050
4. 1.010 1.395 0.755 0,052
47 0.989 1.350 0,685 0.045
48 0.959 1.060 0.661 0.058
49 0.686 1.187 0.623 0,052
50 1.005 1.139 0.877 0,062
51 1.026 1.2 10 0.790 0.064
52 1.0 14 1.127 0,526 0.053
53 1,090 1,098 0757 0 ,074
54 1.120 1.005 0.440 0.059
Control Mean + 2 S.D.: ' 0.1582 •• O.v~"'8 ... 0.1538 .... 0.0760
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Table 7. ELISA results from the second 5 ml HPLC separation of the 26·()\-4
bispecific hybridoma
26-61 ....
2nd 5 ml Separa tion
FRACT ION #
ANTI-CEA'" ANTI~DOX·" ANTI-D OX- Dl lAI.ASSAVUSA"' ' .... ...
40 1.092 0.181 0 .575 0.067
41 \ .087 0.156 0.410 0.057
"
1.135 0.191 0.72 8 OOCll)
43 0.987 0 .319 0.827 0,049
44 1.076 0.518 0.99 1 0.052
45 1.138 0.641 0 .886 0 .052
4. 1.194 0.926 1. 178
41 1.091 0.95 7 1.204 0050
4. 1.085 1.1 13 1.090 0,047
4. 1.190 1.277 0.996 0,061
50 1.110 1.180 0.972 0,063
.. 1..185 1.295 1.129 0,065
51 1.152 0.8 10 1.062 0.062
53 1.212 1.196 1.207 0.059
54 1. 189 1. 132 1.201 0054
55 1.013 1.263 1.127 0.059
56 1.02 1 0.84] 1,042 0 ,048
Control Mean +2 S.D.: · 0.1582 · · 0.0978 "·0,1538 ''' · 0.0760
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for both samplesbUI theintensityfor each sample was not the same
The dual assayresults(Tables 6 & 7) for these sampleswere also minimal
where none of the wellsgave absorbance readings greater than the control mean+/- 2
standard deviations
III 7.3 16-61-105 mlllPLC Separati on
III 7.J (a) IIPLC Profiles
There were three consecutive5 ml HPLCseparationsfor this hybridoma. The
profiles (Figures30, 31&32) werenot exactly the same. Thefirst separation (Figure
30 ) gave a second peakregionwhicheluted between 53 and64 minuteswhereasthe
second(Figure31) and third (Figure 32) separationsgave a secondpeakregion
between35 and 55 minutes
III ? 3(b) ELISA Results
Although the separationprofile of sample 1(Figure 30)wasdifferent from the
other samples,the assay results revealed the samegeneral pattern of high activity in the
middle fractions(Table8). The dual activity assay gave a peak activity region which
corresponded withpeak regions of the anti·CEA, anti-Dox and anli·DQX-BSAassay
results. The meancontrolabsorbancevalue for thedual assayin Ihis casewas 0.0830.
The mean + 2 standarddeviationswas0.0948. Fractions 55 throughto 63 remained
above this value.
Only the anti--CEA assaywas completed for the secondseparation sample. This
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Figure 30. First quantitative HPLCabsorbanceprofile of ascitic fluid containing26-61-
10 bispecificantibody. A 5 ml sample was loaded and elutedfrom a hydroxylapatite
columnusing a 60 mM to 360 mMphosphate buffer gradient. Fractions were collected
at I minute intervals and absorbanceread at 280 nm
115
Pea k 1
Peak J Peak 4
Peak 2
Figure 31. Second quantitativeHPLC absorbance profileof asciticfluidcontaining 26-
61·10bispecificantibody. Details as for legend10Figure 30.
116
-!
Peak 1
P:OMl'C<lk4Peak.7 \..
Figure 32. Third quantitative HPLC absorbance profile of asciticfluidcontaining 26-
61-10bispecificantibody, Detailsas for legend to Figure 30.
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Table 8 ELISA results fro m the firs! 5 ml HPLC separat ion of the 26 ·61·\0 bispeciflc
hybridoma
26-6 1-10
tst SAM PL E
FRACT ION N
ANTI·CEA " ANTI-DOX .... ANTI -DOX- DUAL8SA ...... ASSAV .......
53 1.185 0.221 0.187 0.098
'"
1,087 0.138 0,207 0.095
S5 ).105 0.223 0.27 1 0. 101
56 1,109 0.306 0.406 0. 111
57 1.067 0.383 0.680 0.115
58 1.168 1.031 0.837 0.110
59 1336 0.588 0.912 0.147
60 1.315 0.968 0.853 O,IOJ
61 1.266 1.495 0.942 0.10 1
"
1.051 0.306 0.538 0.092
63 1.113 0.307 0.468 0.098
64 1.296 0.187 0.434 0.090
Control Mean + 2 S.D.: " 0. 1910 .. 0 .1155 .... 0.0916 • .. · 0.0948
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wasdone in an attempl lo comparethe second sampler,ac1ioos 10 the third. Once I
similArity was shown. the remaining tests would only need 10 beco mpleted on one of
the samplesas opposedto both This was a safeguardthat would allowmoreof the
fraction volumesto beretainedand wooldresult ina larger volume of the linal pooled
product. Theother tests were therefore undenaken with the third sample. The alll\·
CEAresults were very similar for samples 2 and 3 (Table 9). The anli-DOX and anti-
DOX·BSA assay results indicated gradual peak areas in the middle fractions,This was
verysimilar to the dual assay results (Table9) which gave increasing absorbance values
at fraclion 43 and peakedat fraction number 49 (Figure 33), The meanabsorbance
value for thecontrols in this dual activity lest was 0.0648. The control mean +l· 2
standard deviations was 0.0734. Fractions40 to 56 were higherthanthis value
Dual activity testing wasalso completed for the firstsample. Fractions 53 to 64
were tested (Figure 33) where fraction IJUmber 59 gave the highcS! dualaaivily .
Several fractionswere significantly higherthan thecontrol mean +/- 2 standard
deviations (0.0948)
III 7.4 57-11-25-175 ml HPLC Separation
III 7.4(a) HPLe Profilfs
There were slight variations in the three HPLC profiles of the 57-11-25·17
(Figures 34, 35 & 36). All three had a second peak region which contained two distinct
peaks. The second peak region oft he first separation (Figure 34) started eluling al
approximately 37 minutes inlOthe procedure andfinished near 58 minutes. Thesecond
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Table 9. ELISA results from the seco nd and third 5 ml HPLC separa tions of'the
26-61-10 bispecilic hybrido ma
0.0916 @0.07340.1155Control Mean +2 S,D.. 0.1910
26-6 1-10 2nd 26--61-10
FRACTIO N SAM PLE J rd SAMPL E
,
ANT I- ANT I- ANT I-DOX - DUA LANT I-C EA* CEA* DOX" BSA*" ASSAY'"
35 0.92 1 1.017 0. 119 0.279 0.074
J6 0.934 1.02 1 0.141 0.285 0.074
37 0.975 1,005 0.150 0.42 8 0.073
J8 0.986 0,932 0.157 0.490 0.07 1
3' 1.004 0.986 0.215 0.3 19 0.072
4. 0,984 1.015 0.160 0.230 0.080
41 1.033 1.003 0.176 0.588 0.077
42 0.886 0.964 0,211 0.40 3 0.083
43 0.970 0.853 0,248 0.379 0,111
4' 0.985 0.868 0,289 0.398 0.125
45 1,070 0,83 1 0.328 0.69 8 0.123
,. 1.213 0.852 0.437 0.469 0.136
47 1.116 . 0,864 0.440 0.556 0.154
48 1.064 1,045 0.328 0.641 0. 183
4' 0.93 5 1,064 0.323 0.43 8 0.396
5. 1.070 1.044 0,310 0.433 0.163
51 1.091 0,876 0.273 0.370 0.179
52 1.196 1.055 0,259 0.389 0.176
53 1.059 0.887 0,255 0.467 0.157
5' Ll5 1 1.010 0.223 0.350 0.163
55 1.043 0.939 0.176 0.344 0.174
5. 1.046 1.02 1 0.144 0.36 2 0.123
. .. ...
.4 o 1s t Sample
D 3rd Samp le
W .3
u
z
<
III
0:
.20
Vl
III
<
.1
35 40 45 50 55 60
FRACTION ., ( 1 minute 'ff"actions)
120
65
Figure 33. Results from dual assaysof 26·6 1· 10bispecificlwbddoma.Testing was
completedon all95 fraction of samples I and 3.Only thesecondpeak region gave
positive results. Theabsorbancewas read at 405 nm
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Peak 1
Figure 34, First quantitativeHPLC absorbanceprofile of asciticfluid containing57-
11·25- 17bispeciticantibody. A 5 ml sample was loaded andeluted from a
hydroxylapatite columnusing a 60 mM10360 mMphosphate buffer gradient
Fractions were collectedat I minute intervalsandabsorbanceread at 280 nm.
.1
r
i Peak 1
IleakJ
I'clik 2
Tl m.. ("' ln ut~"
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Figure 35. Second quantitative HPLC absorbance profile of ascitic fluidcon taining 57·
11·25·17 bispecificantibody. A 5 ml sample was loaded andeluted from a
hydroxylapatite column using a 60 mM 10 360 mMphosphate buffer gradient.
Fractions were collected at I minute intervals andabsorbance read at 280 nm
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l'i l' C<lkl
Peak 2 Peak 3
Figure36 . Thirdquantitative HPLCabsorbance profileof ascitic fluid containing57~
I )·25·17 bispecificantibody. A 5 ml samplewas loaded andeluted from a
hydroxylapatite co lumnusing a 60mM to 360 mM phosphate buffer gradient
Fractions werecollectedat I minuteintervals andabsorbanceread at 280 om
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andthird separat ions(Figures 35 & 36) showed the second peak region eluting
between 40and 62 minutes. Both of these separations were very similar in appearance
However, the first separationwas slightlydifferent in appearance wherethe first peak
of the second peak region wasslightly larger.
III 7.4(b) ELISA Results
The anti-CEAresults for all three separations gavea very similar pattern 10 the
101separation resultsfor thai particular peak region. The an l i~DOX and anti·DOX-
BSA re sults for each of the separations (Tables 10,11 & 12) wercvery similar in
intensity and revealed the general patternof peakingwithinthe middle fractions
The dua l assay results revealedthat there were some wellsin each of the separations
thathad absorbance readings significantlyabove the control.The control mean +/- 2
standard deviationswas 0.0661. However. there were not many results above this
value. Those that were greater were not as significant as the results with the 26-61- 10
hybridoma(Tables 8 & 9). Fraction #38(Table 10) gave a very high volume. However.
sincethis was the only fraction whose volume wasconsidered to be insufficient to
permit concentrationand then subsequent testing in the mlcrccytostasis assay.
III 8.0 IN.YlI.BQ MICROCYTOSTASIS ASSAYS
III 8.1 Mean ic ; values
Ahigh CEAexpressingcoloniccancer cell line (SKCOI) and a low CEA
expressingcolonic cancer cellline (r:OLO 320 OM) weretested for their response to
Table 10. ELISA results from the first 5 ml HPLC separation of the 57- 11-25-17
bispecific hybridoma
12 5
57-11-25-17
i u S ml Separ ati on
"'RACfION #
ANTI-eEA" ANT I·DOX"'" ANTI -DOX - DUAL ASSAY
USA""''' ........
37 0.976 0.126 0.449 0.060
38 0877 0.179 0.454 0.069
39 1,039 0.176 0.590 0.062
40 0.959 0.272 0.574 0,060
4 . 0.870 0.286 0.6 15 0.06 2
42 0.845 0.513 0.933 0.059
43 0.898 0,681 0.933 0.066
44 0.733 0.567 0.876 0.059
45 1.009 0.517 0.885 0.067
46 0.985 0.429 0.791 0,055
47 1.111 0.426 0.777 0.054
48 1.170 0.423 0.889 0.060
49 1.075 0.479 0.902 0,057
50 1.0 19 0.982 0.702 0.OS7
51 1.092 0.380 0.956 0,055
52 1.062 0.396 1.150 0,057
53 0.982 0.330 0.863 0,047
54 1.107 0.347 0.990 0.052
Control Mean + 28, D,: • 0.1454 • • 0.0635 ... 0,0728 ····0.0661
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Table I I. ELISA results from the second 5 ml HPl C separation of the 57·I I': l5·17
bispecific hybridoma
!'7· 1 1·1..~17
FRA CfION I#
2n d 5 rnl ~plf".lion
ANTI·C EA· ANTI- DO X· · ANT I· DOX- Dl IAI . ASSAv
8 SA·" ....
'0 '-0 16 0 . 153 0 444 0.rlU7
"
0 ,92 1 0 , 195 0 .508 0 ,075
42 0.823 0.2 16 0 .779 OOM
43 0.9 16 0 .330 1.030 onSI)
"
0.908 0 .38 7 0 ,970 D.OM
45 0.906 0 ,386 0979 0077
,. 0.894 0 .48 5 1.216
47 0 ,984 0 .567 1.044
,. 1.00 5 0 .615 1 056 0 060
49 0.897 0.483 1.192 0,1.162
SO 1.002 0 .672 1. 158 0 064
51 1.058 0 .544 0 984 0 .051'
52 0.933 0 .536 1.146 o.ose
53 0 ,90 1 0 .70 1 0844 0 .OS8
54 0 ,878 0 .72 2 0 94] 0 060
5S 1.105 0 .65 9 1.018 0,065
5' 1.140 0 .797 1.154 oosr,
57 0,94 1 0 .594 1.148 O.OS(,
58 0936 0 .37 9 0 ,842 0,072
59 0.947 0 .368 0 ,764 OOM
ConlroIMea n + 2S ,D.: · 0 .1319 " 0.1155 " · 0 ,<)916 •.. · 0.066 1
Table 12 ELISA results from the third 5 mlHPlCseparationof the 57-11·25-17
bispccific hybridoma.
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57- 11-25-17
3rd S M L Separation
FRACT ION #
AI NTI·CEA'" ANTI - DOX.... ANTI · DOX- DUAL ASSAY
BSA"'u ,,"'''' ..
40 1.084 0.262 0.333 0,056
41 1.115 0 , 130 0.378 0,053
41 1,073 0 . 143 0.525 0,054
43 0.790 0.366 0.722 0.064
44 1.117 0 .158 0.714 0,056
45 1.092 0. 198 0 ,872 0.064
46 1,044 0,276 0.901 0.057
47 1.155 0.250 1.065 0.067
48 0.9 17 0.409 0 .969 0.078
4. 0,8 13 0 .562 1.006 0,060
50 1.082 0.686 1.192 0,063
5 1 1.151 0 .539 1.131 0,057
52 1.120 0 .544 0,978 0.060
53 1.119 0 .465 0,940 0,058
54 0.566 0 .5 11 0,914 0,064
5S 0.918 0 .623 0.930 0.058
56 1.190 0.59 \ 1.008
57 1.141 0.668 0.951 O.os7
58 1,024 0 .464 0.861 0.057
5. 0.669 0.588 0.545 0.055
Control M ean +2 S.D .: .. 0.1454 . , 0.0847 . .. 0.0728 •..· 0 ,0661
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dcxorubicin. T he drug alonewas addedto the cells in log dilutions. The toxicity was
determinedby comparing theabsorbance in test we lls10 that of the control wells. This
permittedcalculation of II %cell survival value for eachdilution of drug These values
were then placed on II sigmoid curve to determine which dilutiongave 50% inhibition
of cell growth, or the 1C-.n value. Thecytotoxicity assay with DOXalonewas
performed at thesame timeas the testing withBSMab lind DOX
An IC~ value ofOOX forthe SKCOI cell line had been determinedin this
laboratory pre viously (Ford et al, 1989), The mean ICsovalue wasreported as being27
nglro!. The va luecalculated in my experiments was 28.5 nglmlwith a standard
deviationof3 . 14(Table 13). However. the value for the COLO320 DMcellline had
not been determined prior to this project. It was determined asbeing 116] nglmlwith a
standard deviation of 167,9 (Table 13).
III 8.2 ln Yi..l.tv: Antibody Testing Using the SKCOI Ccicreerat Cancer
Cell Line
III 8.2(8) BispeclficMonoclonalAntibody 26-61-10
These tests were completed in triplicate in order to veril} the effect of the test
antibody. Figure 37 illustrates a decrease in survival of the cellswith increasing
concentration ofdrug. It alsoshows a distinct differencein percent survival between
the drugalone andthe testvalues using the log dilutions ofantibody anddrug. The test
values were clustered together anddid not show anydifferencesin percent survival
when comparing test results for eachantibody dilution. However, the le ll ) values
Table I] . Summary of lC'lIResults
Mu n ICN Mt an lCM
!\Iran 16-61-10+-DOX(netml)" Ag8+DOX (ng/mW"Crll
line
IC,. DOX
Antibody Ceneemraucn (JIg/ml) Antibody Connntralion (f.Igfml)
(ng/mll"
ID I e.t 0.0 1 ID I o.t 0 .0 1
COW 1163 +/- IS33 +/- 880 +/- 1147 +/· 984.7 +/~ 1721 1054 .7 1283.7 1204 6
320 DM 167.9 254 410.S 639 .4 3.14 +/- +/- -t, +/·63.9
618 239.9 712.5
28.5+/- 14.0 +/. 14.0 +/- 12.0 +/- 12.7 +/- 31.3 24.7 39.0
3 1 +1-
SKCOI 3.14 9.6 5.3 1.81 3.11 +/- +/. +/.
7.2 1
(P<D.OS)" (P<O.OI)" (P<D.OOl)" (P<D.OI)" 9.5 4.• 19.7
based o n 6 lest s
basedonJ tests
+ Significantly different to IC'lIfor DOX by student T le st
13 0
~ 0 10 ug/ml + OOXo 1 ug/ml + OOX6 0 .1 ug /ml + DOX, 0 .01 ug /ml + OOX• COX alone~
100 10' 10 2 103 10<4
ORUG LOG OILUTIONS (ng/ml)
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Figure37. Result from MTT assayusing purifiedBSMab 26-61-10andDOX with the
SKCOI colorectalcell line. The BSMabwasadded inlog dilutionsfrom10 10 0.01
lJ.g1ml.DQX was added with thebispccificand alone(control) in log dilutions from
100010 I ng/rnl,
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(Table IJ & 14) indicate that all of the lest resultswere smaller than the mean ICso
valuefor DOX alonewith thiscell line
Figure 38 also illustrates the greater decrease in survivalof the SKCOI cells
when using the bispecific 26-61-10anddrug dilutionstogether as opposed to using
doxorubicinalone. The IC~ values(Table 14) for the antibodydilutions were
significlI.... t1y lower than those for doxorubicinalone.
The third graph for SKCOI using 26-61·10and doxorubicin (Figure 39) also
indicates a percent survivaldifferencebetween the DOX alone result and antibody+
drug tests The calculated IC51l values for these results are shown in Table 14. The
mean ICsovalues for these threeassaysare summarized in Table 13 and fromthis it can
be seen that BSMab+ DOX gave a substantiallyreduced IC~ comparedto DOX alone
forall BSMabconcentrations that were tested
The 'lit survival values for the antibody alone control wellsfor eachof the
figures(Table 15) illustrate that there was littleor no effect of the antibodyalone on
the cells. M('I:;t values fluctuated near 100% with no great drop in % survivalas was
seen with theantibody + drug test values
III 8.1(b) Ag8 Non-Spedfit Antibody
All three tests using the non-specificAgSantibodyand doxorubicindilutions
with the SKCOI cell line (Figures40, 41& 42) were verysimilar. All three figures
illustrated the close proximity of the test results to those of the DOX alonecontrol
values. In Figure 40, there wasone Ie'll result (0.1 f.I g1ml AgS+DOX) which
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Table 14 Calculaled IC,..values of DOX + 26-6 1-10 ba pecific anlibody and DOX +
Ag8 non-specific antibody using the SKeOI cclorectal cancer cell line
BISPE(;IFIC CALCULATED
16.61·10 IC~
ANT IBODY TESTS FiguR'37 Figurt38 .i~urt J9
10pg/ml 10.)] 456 1.2056 12 24.<,.1955
I pg/rnl 8.113348 17.592()J 15.7S5()4
0.1 p g/rnl 8.971718 15.00J 86 11.6288
0.01 p g/rnl 7.610129 12.8610 1 17.()5198
DOX al one 41.03033 23.45008 32.42518
NON·S PEC IFIC
Ag8 ANTIBODY Figure 40 Fi~u", 4 1 Fi~urC" "l
TES TS
10pg/m l 4 1.14354 21,68 152 )0 ,84934
Ipg/m! 27.15968 18.54718 27.55846
O.l pg/rnl 60.52837 22 94955 JJ.4254 6
0.01 Jlg/m l 29,2653 1 39.03962 25.38895
DOX alone 38.31267 18.72450 18.44"90
100 10' 102 103 10 4
DRUG LOG DILUTION (ng/ml)
a 10 ug /ml + COX
o 1 ug /ml + OOX
.Il. 0 .1 ug /ml + COX
II 0 .01 ug/ml + OOX
• DOX alone
;/.
z
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Figure 38. Resultsfrom MIT assayusing purified BSMab26-61· 10 andDOX with
the SKCOI colorectal cancercell line. The BSMab wasadded in log dilutions from 10
to 0,0 1 ug/ml.DOX was added withthe bispecificandalone (control) inlog dilutions
from 1000 to 1 nglml
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c 10 ug/ml + DOX
o 1 ug /ml + DOX
A 0 . 1 ug /ml + COX
x 0.01 ug/ml + OOX
• COX alone
1~ 10 ' 1~ 1 ~ ,~
DRUG LOG DILUTIONS ( n g/ml)
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Figure 39. Results from MIT assay using purifiedOSMan 26·6 1· 10 and DOX wilh the
SKCOI colorectal cancer cell line. The DSMab was added in log dilutions from 10 to
0.01 )lWmLDOX was added with the bispecific and alone (comrol) in log dilutions
from 1000 to I nglrn!
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Table 15, Calculated percent survival of SKCOI when using bispecific antibody (26-
6 1 ~I O) and non-specific antibody (Ag8) controls,
~
BISPEC IF IC Ofo SURVIVAL
26-6 1· 10
ANTIBODY
Figure 37 Figure 38 Figure39CONTROL
IO,.glml 87. \ 96.7 88.9
I pgfml 89.4 117.8 102.3
O. I ,. g/rol 76.4 108.6 91.9
O.Olllglm l 72.4 10] .5 108.3
NON·SPEC IFIC
Ag8 ANTIBODY Fig ure 4C Figure 41 Figure 42
CON TRO L
IO,. glml 96.6 90.4 105.4
I p gfml 93 .7 88.1 91.0
O,l,.glml 104.1 97.5 105,9
0.01 pglml 111.7 89.4 81.4
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D 10 ug/ml + COX
o 1 ug/ml + COX
.0 .1 ug /ml + COX
• 0 .01 ug /ml + COX
• COX alone
10 0 10 ' 10 2 10 3 10 "
DRUG LOG DILUTI ONS ( ng /ml )
Figu re 40. Results from MTT assayusing non-specific Mab AgSand DOX with the
SKCOI colorectal cancer cell line. The non-specific antibody was added in log dilutions
from 10to O.OI Ilg/mJ.DOXwas added withAg8 and alone (control) in log dilutions
from 1000to I n.,yml
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o 10 ug /ml + COX
o 1 ug/ml + DOX
• 0 .1 ug /ml + COX
II 0 .01 ug /ml + OOX
• COX alone
100 10
'
10 2 10 3 10 "
ORUG LOG DILUTIONS (ng/ml)
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Figure 41. Results from MTTassay using non-specific AgS Mab and DOX w ith the
SKCOI cotorectet cancer cellline. The non-specific antibodywas added in log dilutions
from 10 to 0.0 1 llglml. DOX was added with AgSand alone (control) in log dilutions
from 1000 to I nglm!
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a 10 u g / ml + OOX
o 1 u g / ml + OOX
... 0 .1 ug / ml + OOX
• 0 .01 ug /ml + COX
• OOX alone
10 0 10' 102 10 3 10 4
DRUG LOG DILUTIONS (ng/ml )
Figure 42. Results from MIT assay using non-specificMab Ag8 and DOX with the
SKCOI cclorectal cancer cellline. The non-specificantibody wasadded in log dilutions
from 10 to 0.0 1 v.glml. DOX was added with Ag8 and alone (control) in log dilutions
from 1000 to I ng/ml
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substantially exceededthe \00010 value for the controlwells withmediumonly. This is
shown in Table 14
Figure 42 showsa greater variation than the resultsshown in Figures 40 and
41. However, all lest IC,ovalues (Tables 13 & 14) were within range of the mean +1- 2
standard deviations or the calculated doxorubicmIC~ for that cell line.
The% survival for the AgS antibodycontrols in all three of these tests (Table
15)were close 10 the 100% value. As with the antibody alonecontrols for the 26-61-1 0
bispecific Meb, these values didnot showany great decrease in % survival in contrast
10those seen withthe test BSMah+ DQXsamples
III 8.3 In Y.ittD An tibod y Tesn ng Using COW 320 OM Cctereetat Cancer
CeJILine
III 8.3(1) Bispetific Monoclonal Antibody 26-61-10
The inYiill!results when using the bispecitic Mab26-61·10 + DOX with the
low CEA expressing cellline, COLO 320 OM, were consistent. Allof the test values
fluctuated around the OOX control result (Figures 43, 44 & 45) showing no significant
drop in the IC50 values. Most of the calculated IC,..values for this series oftest s (Table
16) were within the mean»t; 2 standard deviationsrange of the calculatedICsovalues
for COLO 320 OM with OOX alone (table 13). The only values lower than this were
the 1. 0.1 and0.01 ~g1mI26-61-lObispecific antibody + DOX samples in Figure 45.
The percent survival of the antibody controls using the bispecificantibody alone
(Table 16) revealed variations in survival which were verysimilar to those seenwith
14 0
D 10 ug/ml + COX
o 1 ug/ml + COX
.0 . 1 ug/ml + DOX
• 0 .01 ug/ml + DOX
• OOX alone
10 610' 10 2 10 3 10" 10!5
DRUG LOG DILUTIONS (ng/ml )
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Figure 43. Results from MIT assayusing purified BSMab 26-61-10 and DOX with the
COLO 320 OM colorectel cancer cell line. The BSMab was added in log dilutions from
10to 0.01 pg/ml. DOX was added with the BSMab andalone (control) in log dilutions
from 10000 to 10 nglml
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a 10 ug/ml + COX
o 1 ug/ml + COX
.t. 0.1 ug/ml + OOX
II 0 . 0 1 ug/ml + COX
• COX alone
10 1 10 2 10 3 10" 10:5 10 6
ORUG LOG DI LUTIONS (ug/ml)
Figure 44. Results from MIT assayusing purified BSMab 26-61-10 and DOX with the
COLO 320 DM colorectel cancer cell line. The BSMab was added in log dilutions from
10 to 0.01 ugzml. DOX was added with the BSMab and atone (control) in log dilutions
from 10000 10 10 nglml
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a 10 ug/ ml + DOX
o 1 ug /ml + OOX
.. 0 .1 ug /ml + DOX
• 0 .01 ug / ml + DOX
• COX a lone
10' 10 2 10 3 10· 10!! 10 6
DRUG L OG DILUTIONS ( ng/ml )
Figure 45. Resulls trom MTT assayusingpurified BSMab 26-61-10 and OOX with the
COLO 320 OM colorectal cancer cell line. The BSMab was added in log dilutions from
1010 0.01 pglmL DOX was added with the BSMab and alone (control) in log dilutions
from 10000 to 10 nglmt.
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Table 16. Calculated Ie",valuesof DOX+ 26-61-10 bispeeific antibody and DOX +
AgS non-specificantibody using COLO 320 OM cclorectal cancer cell hne
OISPE CIFI C CALCULATED
16-(i 1- IO ICM
ANT IBO DY TESTS
.'igurt4J Figurt44 Figurt 45
IOJlWml 1605.644 1743.164 1249 .983
Ipglm) 1212.] 56 1006.606 421.4929
0.1 pglml 1)9:i:10 1624.738 420.8688
0.01 pglm l 170 1.714 912.176b 340.2694
DOXalone 872 .8328 1202.872 1364.761
NON·SPE CIFIC
AgBANTIBODY Figu re 46 Figur e 47 Figur e 48
TESTS
10 pgl ml 2422.376 1182.880 1256.173
IJlglml 1122.603 1484.328 788.4096
0.1 p g/mt 2065.267 1253.187 1116.004
0.01 pg/mt 1137.350 689.7904 1213.305
DOX .lone 1103.412 1263.868 1175.075
'"
the BSMab+ DOX values
III 8.J(b) Ag8 Non..spttiftr Antibody
As with the bispecific Mab 26-61.10, the results for the Ag8 ron-specifle
antibody+ DOX dilutions were verysimilar to that of the OOXcontrol for each set of
tests (Figures 46, 47 & 48). Manyor tbe Ag8+ DOX tests had 1C'IIl values tha i were
considerably higher than the mean ICsovaluesfor DOX with the COLO320 OMcell
tine (Table 13). When the mean IC~ for Ag8 + DOX for all 3 assays were compared 10
the mean ICsofor DOX for this cellline, noneof the differences reach statistical
significance. The % survival of the Ag8 antibody alone controls for these tests
fluctuated between 68 to )00010(Table 17)
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D 10 ug /ml + DOX
o 1 ug /ml + COX
6 0 .1 ug /ml + COX
Ie 0 .01 ug/ml + COX
• COX alone
10' 10 2 10 3 10.... 10 5 10 6
DRUG LOG DILUTIONS (ng/ml)
Figure 46. Resultsfrom MTT assay using non-specific MabAg8and DOX with the
COLO320DM colorccta! cancer cell line. The non-specific antibodywasaddedinlog
dilutionsfrom 10 to 0,01 ~g!ml. DOX was added with Ag8and alone(control) in log
dilutions from 10000 to 10 ng/ml,
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D 10 ug/ml + OOX
o 1 ug/ml + DOX
.6 0 . 1 ug/ml + DOX
x 0 .01 ug /ml + COX
• COX alone
10 1 102 10 3 10 '" 105 106
DRUG LOG DILUTIONS (ng/ml)
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Figure 47. Results from MTT assayusing non-specific Mab Ag8 and DOX with the
COLO 320 DM colorectat cancer cellline. The non-specific antibody wasadded in log
dilutions from ]0 10 0.01 ",glm!. DOX wasaddedwith AgSand alone (control) in log
dilutionsfrom 10000 to 10 ng/ml.
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D 10 ug/ml + COX
o 1 ug/ml + OOX
.6 0 .1 ug/ml + COX
II 0 .01 ug/ml + COX
• DOX alone
10' 10 2 10 3 10· 10 5
DRUG LOG DILUTIONS (ng/m l)
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Figure 48. Resultsfrom MIT assay using non-specificMab AgSand DOX withthe
COLO320 OM colorectal cancercell line. The non-specificantibodywas addedin log
dilutionsfrom 10 10O.oJug/ml, DOX was addedwith AgSand alone (control) ;,Jlog
dilutions from 10000 to 10 nglml.
Table 17. Calculated percent survival orCO LO 320OM when using bispecific
antiboody (26-6 1-10) and non- specific antibody (AgS)
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DlSP ECIFIC Ofo SURVIVAL
26-6 1·10
ANTIBODY Figure4J Figure 44 "'igll~ 45
CON TROL
tOpglml 9 1.2 88,1 79.5
lllglmi 105, 1 80.6 64,0
0,1 pgfml 102 .0 no 87,8
O.Olllgfml 90 .2 90.9 64,4
NON·SrECIFIC
Ag8 ANTIBODY Figur e 46 Figllre4? fo'igllre48
CONTROL
IOpglml 90.0 98,2 97,6
I Jlglml 8 1.8 100.1 100,5
O.lpgfrnl 72 .5 68.3 91.8
O.OIJ.lgfml 76 .9 77.5 ss:
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CHAPTER IV
DISCUSSION
IV 1.0 ASCITIC FLUID PRODUCTION AND PROTEIN A
COLUMN PURIFI CATION
The initial requirementfor this study wasto produce more of the secreted
product of the seven bispecifichybridomas than co uldbe obtained from tissue culture
alone. To do this, Balb/C mice were inoculatedintraperitoneally with the hybridomas
In the experiments describedin this thesis, 104 mice were inoculated and for each
hybridoma approximately SO· 100 mlof pooledasciticfluid wasobtained. However,
after initial purification by protein A affinity chromatography thevolume of recovered
semi-purified ascitic fluid wasgreatly reduced(range 5 - 20.5 ml). For sixof the
hybridomas the proteinconcentration,as assessed by absorbance at 280 om, was
reasonably consistent (range I ,7S - 2.52 mglml). However, the yield from hybrid 26-7-
35 was very low at 0.545 mg/ml. There is no explanation for this apparent discrepancy
other thanthat this particularhybrid has a low rate of secretion of antibody or that a
particularantibodysubclasswas not binding to protein A. However. if there was a
subclass not binding, then it did not include theBSMabas all theunbound material and
columnwashingswere tested for dual activityand were found to benegative. Muchof
the protein A-purified materialfor the seven BSMabs wasused for the initial
standardisation procedures, resulting ina shortage of purifiedproduct for HPLe
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preparative purificationand inrilm. microcytoSlasisassays
Prote n A purificalion is ooted as being I much be neraffinity purifYing
procedure formurine180 10. !gGa and IgG] but te be not $0 good forIgG , purification
(Hermansond al, 1992). The parental ll -28S-14 anli-CEA used in theO ncology
Researchlabisan IgOl and hasusually been purified in thismanner with efficient
recovery or produet. Many groups have used protein A purification 85 a primary
bispecificantibody purification procedure (Mo relli er al, 1994; Dietschct al. 1993;
Duke-Cohanet ai, 1993), However, all cases involved the use ofat lcast one IgG1a
parental monoclonalantibody. Protein Gis suggested for usewith antibodiesthet do
not bind wellto proteinA (Hermanson et al, 1992) and hasbeen usedin such cases
( Xiang et ai, 1992). The decisionto useprote inArather than proleinG in theresults
presented in this thesiswas based on thefact that although protein G has beenused by
a number ofinvesligators. it isnot recommenlkd for the purificatiooof mouseIgO as
its removal from proteinG canbediffiaJlt (Andrewet al l994). Also. the parental II·
28S·14 monoclonalantibodyisan IgO I and prdiminary attempts to purify it with
protein G hasresulted in a verylow recoveryofanti·C EAantibody. presumably due to
the problemof'not being able to completely disrupt its binding to tilepro teinG(F ord.
unpublishedobservations). Henceit seemed more appropriate to useproteinAfor the
initialpurification of the BSMabs
Theonly other option that co uldimprove the initial purilicationstep is havinga
purificationcolumn which was labelled with CEA. This would directly pur ifyany
antibody with anti.(EAactivity, includingthe BSMabs Antibodies witho ut lheami-
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CEAac tivitywould bewashedout or the columnleaving fewer subclasses10analyze
withthe IIPLC method. However, in theabsenceof sucha column,the protein A
column would be themore logical choice.
IV 2.0 PRODUCTION O F CONJUGATES
IV 2.1 DOX·BSA Conjugate Formation
Threeseparate DOX·BSAconjugationswere done, The firsttwo (Figures 2&
3) were verysimilar intheir ratioof protein to drug.The conjugatedproduct, beingof
larger mass, eluted out from theSep hadexco lumnat the firstpeak. The secondpeak
consisted of non-conjugated drug, In thethird conjugation(Figure 4)there wasmore
drugper protein molecule, as canbe seenfrom thehigh reading at 495 nrn The o nly
difference inthe procedure between thefirst twoconjugations and the last wasthe first
two procedureswere done over two days. It involved anovernightstorage period at
411(: while thelast procedure wascompleted withinone day. This maybe a possible
explanationfor the difference seen between the first two conjugationsand thethird
IV 2.2 C EA·HRP Conjuga te Form ation
With the CEA·HRP conjugation(Figure5) the entire 403 nmpea k wasseen
within the 280nm peakindicating that allthe HRPwas associated with CEA. The
eluted materialwas proven to beCE A·HRP bytesting it against the parentalanti~CEA
antibody (Figure 6). The CE A·HRP conjugate onlybound to the coating parental
antibody butnot to theplate coated withcont rolAgS antibody. The 1140 (5%) dilution
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gave a high absorbance reading andyet was sufficientlydilute to conservethe reagent.
and thiswas chosenas the dilut ion10 be usedin thedualactivityassays.
IV ].0 STAN DARDIZ ATION O FTHE IIPLC PROCEDUR E
IV 3.1 Purifi4:Rlion of 11_285- 14
In o rderto obtainexperience with HPLC analysis. the parental anti-CEA
mon oclonal antibodywas the first antibody purifiedonthe ~IPLC co lumn. This was
done usinga 60mM to 180 mM phosphatebuffer gradient andwas found10 giveone
anti-CEApeak, asexpected. The profile (Figure 7) illustra tedtwo peaks.However,
anti·CEAELISAtesting (Figure 8)demonstrated that this firstpeak wasan injection
peak. Thiswas anartifactof all HPLC purifications anddid notcontainanyprotein
Th is experiment also indicated. approximately, where one couldexpect theparental
ant ibodyto elute when the BSMabswere being purified
IV 3.2 Purification orBSMab 26-61-2
The fonnation ofa hybridomax spleen cellorhybridK hybridomabispecff l c
antibodyresults in the formationofmultipleantibodies(Figure l). Not only doesone
get thepare ntalantibodiesbut alsohybrid moleculeswith thebinding characteristicsof
each of the fusion partners(Su resher ai , 1986). Because o f this one wouldexpect to
find various numbersof immunoglobulin chaincombinations perhybrldoma. This
shou ldthen correspond to variouselution peakswithina HPLCpurification profile.
26-6 1·2gave sixpeaks (Figure9(a»)but again the firstwas shown10 be
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insignificant (figure 9(b», Theelution time of the sixth peak(Figure9(8»
correspondedto thatof the elution timeof the parentalanli-eEA monoclonalantibody
(Figure 7). The ELISAresultsin Figure9(b) alsoindicated thai thetwo peakswere the
sameantibody. Likewise,the second peakgave high anli-DOXandanti-DOX-BSA
activity. Thisindicatedthat thispeak probablycontainedthe anti-DOX parental
antibody. Peaks fourand fivegave highanti-CEAactivityand relatively highanti-DOX
andanti-OOX-BSAactivity (Figure 9(b» indicatingpotential bispecificactivityin these
peaks. Onthe basisof these ELISA results, thispeak regionwas chosen for the study
of the otherBSMabs
IV 4.0 ANALYTICALHPLe PU RIFICATIONS OF BlSPECIFIC
ANTIBODIES (I mIINJECTIONS)
Theproducts of sevenhybridomaswereinitiallyanalysedusing I mlinjections
Asexpected from thepossible combinations ofheavyandlight chainimmunoglobulin
genes (Suresh et ai, 1986) allseven hybridomas secretedproducts with different elution
profiles. Various shaped absorbancepeaks anddifferentpeak locations indicatedthat
each sample had slightly different combinations and different amounts of various
combinations of geneproducts. Hydroxylapatite HPLCseparates macromoleculesby
differential surfacebinding10phosphate or calcium siteson the matrix. Thedifferential
surfacebindingis ionic, but alsohas specific affinity properties,andit is these
propertiesthat havemade h a commonmethodfor the separationof proteins,
especiallyenzymesand antibodies. Thisis whyitwas selectedfor use in thisthesis
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The ELISA resultsalso varied with each hybridoma. In all cases. the anti·CEA
activity started withinthe firstt en fractions. II then gradually increasedand peaked
around the region of the last absorbance peak for that hybridoma. The activity then
decreased rapidly. This indicates that the anti-CEA parental combination was located in
the last peak and that earlierpeaks probably contained antibody with onlyone anti-
CEA comb ining site. The increasing ELISA acti vity indicated that the amount of this
monovalent combination was increasingin concentration in subsequent peaks. In faci
twice 115 many monovalent antibodies could bind per plate than the parentalbivalent
antibody. Therefore, if monovalent concentrations are high enough then thesepeaks
could give as strong or stronger anti·CEAresponse than the parental antibody itself.
This could explain the strong anti-CEA activity in the regions outside of the parental
anti-CEA monoclonalantibody combination
Apart from the anti-CEAactivity, there wasanti-DOX, antj-DOX-8 SA and
anti-BSA activity in thevarious fractions. The anti-DOX was expected inlhe first peak
region as wellas in the second peakregions of each HPLC profile. Thefirst, as we
expected, was the parental anti-DOX combination. The second peak would have ami-
DOX because of the bispecific antibody in that region. Allhybridomashadhigh anti-
DOX activity in the first peak region but not all hadhigh activity in the second peak
region. In some cases the anti-DOX-BSA or the anti·BSA activity was muchgreate r
(Figure 18). It was suspectedthat if the antt-Do x activity was low and the anti-nS A
was high in the second peak region, then the efficacy of the bispecificwith DOX would
be poor. 26-61-10 (Figure 18) is an example of such a case. Anti-DOXactivity was
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very low andthe anti-OOX-BSAactivity was higher. Evenmore discouragingwas the
anti-USA activity for this hybridoma. Theanti·BSAactivity was just as high 85 the anti-
CEA, but yet the dualactivity assay(Table 2) indicated that this hybridoma had the
best bispecificactivityof all the hybridomas. Thehigh anti·BSA activity of several of
these hybridomas cannot be fully explained, particularly as the hybrids were originally
selected on the basis of their high anti·DOX-BSAactivity and low anli-BSA activity in
'subtraction' ELlSAs before they were clone d (Reddy, 1993; Reddy& Ford. 199 3).
However, it appears that this is not an indicator ofa poor anti-CENanti-DOX
bispecific antibody. In fact, the resultsfrom these assays mayindicate that ami-BSA
activity is not a criticalassay. The most important test for a bispecificantibody act ivity
is the dual specificity assay.
Most studiesofbispecificantibodies using HPLC only include the ELISA
results of the main elution peakfractions(Xianget al, 1992: Dietsch et ai, 1993)
However, in this studyall fractions were tested and the ELISA results were graphed.
This was done in order to get an idea of how each hybridomawould respond to the
various ELiSAs and to help verifywhich fract ions shouldbecollected for the in.Yi..tIa
microcytostasis assays
IV 4.1 Dual Activily Assay
The dual activity assay did not produce ashigh absorbance readings 85 the other
ELiSAs. This can be explained by the nature of the test itself. The dual specificity assay
relies on the affinity of both antibody combiningsites ie. theanti-Dux ann of the
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BSMab to bind 10 the DOXor DOX-BSAcoated plate and theanti·eEA arm of the
BSMabto bind to CEA-IIRP. Both of these steps willbe affectedby affinity to a
greater degree than the other ELiSAs.as explained below. Theanti-eEA ELISAfor
BSMab relies ononly oneof the antibody combiningsites, theRllIi-CEA.the test of the
assayrelies on the bindingof an anti-mouse Ig to bind 10 the heavyandlight chains of
the BSMab and does not rely on the affinityof the other antibodycombining site of the
BSMab. The sameappliesto theanti-DOX ELiSAs. From a theoreticalpoint of view
much lower absorbance readings would be expected in the dual specifici ty assay. and
this is exactly what was found. Asa consequence orlhis. a reading greater than the
mean plus 2 standard deviations of the control valuewas takenas being significant
IV 5.0 QUANTITATIVE HPLC PUR IFICATION OF BISPF.CIFI C
ANTIBODIES
Four of the oriBinalseven hybridomas ( 26-61. 1, 26.61-4,26·61· 10 & 51·11·
25· 17)were selected for further preparativeanalysisbased on ELISAresults. protein
concentration and final volume of protein Apurifiedascitic fluid. As mentioned earlier,
the anti·BSA ELISA results were used originally asa major determlniugfactor for this
selection process. If theanti·BSAactivity for a givenhybridoma was higher thanthe
anti·DOX response thenit was originallythought that this hybridoma would net bea
good choice for further testing. However, the in Y.itm responseof 26-61· 1O(Figures
37, 38,39,43, 44 & 45) provedthat this was nOI so.The ELISA test with the most
reliance was of course thedual activity assay.The best response, as determinedby the
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dual assay, camefrom26--61-10, 57-11-25-17 and26-7-35(Table 2). 26-7-35 was not
selectedfor quant itativeanalysisbecauseboth its total volumeand theprotein
concentrationwere toolow (TableI ). 26-61-2 and57-9-6-4were alsorej ected on the
basisof volumesavailable, as wellas, in the case of57-9-6-4, its lowresponse in th e
dualassay (Table 2)
Th e HPLC profiles for the5 ml injectionswere not significantly differentfrom
thoseof the I ml profilefor eachhybridomawi th theexceptionof thefirst 5 ml
injection for 26-61- 10 (Figure 30). Thiswasascribedto poorequilibration of the
columnbefo rethe elutionprocessstarted.
T he ELISAassayswerecompletedon thesecond peakregionof all four
hybridomasbecauseprevious ELiSAs indicated thatthe blspeciflc activity wasin thi s
region.T he ELlSAs were consistent withthe results obtained in theprevious tests
doneon the I ml HPLC separations. However, thedual assay results were different .
The 26-61-10dual assay results(Figure 3]) showed muchhigher values than those
obtained with the proteinA purified stock sample (Table 2).However, this wasnot the
casewith 57-11-25-17(Tables 10, I I & 12)whercthe valueswere much lower tha n
thoseobtai nedwith thepurifiedprotei n Astock (Table 2). Based onthis test alone,
hybridoma 26-61-10 wasselectedfor furthertesting, The ELISA resultsindicatedth at
the HPLC procedurewasan effective methodof further purifying suchantibodiesfrom
proteinA purifiedasciticfluid. It not onlygave fractionsthatwere nottoo dilute for
ELISAte sting, but alsothe precise monitoring procedure allowedforeasy selection of
fractionswithbiepecilicactivity.
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IV 6.0 lnYilm CHARACTE RIZATION OF 26-6 1· 10BISPECIFIC
A NTIBODY
The inYi.tm rests onthe highCEAexpressing celltine, SKCO I. Ilsing26-61·10
andDOX demonstrated a dramaticdecreasein the doxorubicin le ll' valuefor that cell
line (Ta ble 13) . Figures 37, 38 and 39 illustrate that with DO X atone there is 1\ definite
decrease in survivalwith increasing drug concentrations. However. the decreasein
survivalis more evident withantibody+drug. When usingthe non-specific Ag8
antibody, it was observed that the ICSlldid nor change (Table 13)thus provingIhu126·
61-10 was indeed reactingin an anti-DOXspecific mannerby increasing the killingof
theCEA expressingcoloniccarcinomacells andacting as a 'drug receptor' , focusing
DOXon the cells. The BSMabcontrolsclearly indicate that antibodyalenewas nor
causingthis effect. To confirmthe specificity of'the anli-CEAarmof the RSMnh the
lowCEA expressingCOLO320 OMcolonic cancer cellline wasused. Theresults
(Tahle 15) show thai therewas no increaseincytotoxicityas comparedto DOX alone.
Thisindicates that 26-61-10 did indeed react in an anti-CEA specific manner,focusing
doxorubicinon the CEA expressing SKCO I cellsand therebyincreasingcytotoxicityto
thesecells(Tables 13, 15 & 17). The fact that Ag8, a non-specificantibody, did nol
haveany effect. confinnedthe specificity of the results obtained. The specific targeting
abilityof26-6 1-IOis clearly seen in thesummaryin Table 13.
The results clearly demonstratethat B$Mab 26-61-10 reducesthe ICSl1 for
DOXbut they alsoshow thaiover the close range tested (0 .01Jlglml - 10Itg/ml) the
amount ofB5 Mab does not seem to makemuchora difference(see figures37,38 &
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39). A plausibleexplanationfor this is thai at the lowest concentration of BSMabused
(0.01 Jlglml)all the CEAmoleculesexpressed by the target cellsare saturated with
antibody.Adding 100 or 1000limes more BSMab does not result in any more targeting
of doxombicin10 the target cells and,therefore,the ICsoremainsfairlyconstant. To
confirmthat this explanation is indeed correct, one would need to titrate the BSMab
from 0.01 pg/ml i.e.0,001, 0.000 1, 0,0000 1 etc. and seewhal effect that this would
have on the le St!_The anticipated resultwould bethat as the BSMab concentration
decreased, the IC5l1 wouldgraduallyapproach that of DOX alone.
The actual killing of these cellsby BSMab which has focused doxorubicin to the
cell surfaceis suspected to be viaantibodyinternalization. Of course, the efficacyof
suchan antibody would depend on the nature of the target antigen (Duke-Cohan et al,
1993). Parental 11-285·14 l\nti-CEAantibodyhas been shown to be internalized by
CEAexpressing cancer cells, including SKC01 (Tsaltas et al, 1992; Tsaltas, 1995;Ford
et al, 1996). Theanti-CEA activity of the bispecificantibody wasillustrated in the anti-
CEA ELiSAsand was oftenas intense as the parental antibodyitself. The CEA.binding
ability and the internalizingproperties of the parental anti·CEA should, therefore, have
beenretained in the bispecific.Retaining the ability to be internalized wouldbevery
important for such an antibody. Otherstudieshave shown thai not only do such
antibodies selectivelydeliver the drugto the tumour, but that they can alsoexertan
antidotalor antitumour activity (Morelliet aI, 1994). These authors also found that
their antibody was able to significantlydecrease the DOX concentration in the
intestines of test mice.Also, they foundthat there was significant antidotaleffects in
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these mice whenexposed 10otherwise lethal doses of DQX. It is very likely that the
26-61w10 was effective due 10 inremalisationand may respond innxu in a similar way
Bispecificscreated for the treatmentof Bccclllymphomas have also beenused
successfully inritr2 and in~ {Demanet et al, \994), Such an antibody was
developed to specifically bind to different antigens than the 26-6 1- 10 but still i\
contained the same dual specificity and antibody mediating targeting properties shown
by many bispeciflcs. Theuse of an indiumlabelled bispecilic antibodies in a clinical
study proved that the tumour to blood and tumour 10 liver uptake ratios of colcrcctal
cancer patie nts was improved (Lc Dou ssal ct ai, 1993). However, 7 out of I I patients
did develop a HAMA response. Therefore, more researchis needed to improve such
antibodies for the treatment of human tumours inyjyQ
A similar case occurred with an ovarian cancer study where the blspcciflc
activity was inhibited by the HAMA response (Lamers et al, J995). This is obviously
the most limiting factor of using such antibodies inclinicalstudies and will definilely
have to be addressed with 26-61-10, if it is to be used in clinical studies. An allempt is
currently being made to developa chimeric humanizedMab derived from the parental
11-285- 14, The Fe portion will, in fact, become a human Fe thereby reducing the
chances of a HAMA response. It will be reduced because most of the HAMA response
is directed towards the foreign mouse Fe, Once the process is completed a chimeric
version of 26-6!·jO could be produced. This would reduce the chances of this antibody
elicitinga HAMA response. complexingwithanti-mouse antibodies and thereby being
prevented from reaching the desired tumour target.
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IV 7.0 CON CLUS IONS ANDSUGGESTED FUTURE RESEARC H
Sevenhybridomas. selectedpreviously COf anti-eEA and anl....OOX activity
(Rtddy, 1993; Reddy&. Ford. 1993) havebeen purifiedusingprotein A affinity
chromatography and analyticalHPLC profiles havebeen obtained forall of them.
Analysis of the HPLC fractionsby ELISA for anti-CEA, anli-DOX. anti-DOX-BSA,
anti.BSA and dual activity 10 CEA and DOXindicated which hybridomas to choose for
further research. Four were selected for prepa rative HPL C analysis and ofthese, one,
26-61-10, was shown to have the highest dual specificity activity. Fractions from
preparative HPLC runswith thisantibody were pooled, concentrated and used 10
evaluate the ability of26 -61-10 10 target doxcrubicin 10 a CEA expressing colonic
cancercell line. This study clearly demonstrated that 26-61·10 causes a statistically
signiflCll ilt reduction in the Ie. value for doxorubicin with SKCOI cells. This effect is
specific as: an ' irrelevant' antibody, AgS. did oot cause this effect; the Ie,. valuefor
doxorubicinwith • low CEA eJlpressingcell line wasnot affectedbythe n SMab and
drug together; 26-61· 10 alone. without the presenceofdoxorubicin,had only a
minimal effCdon the viability of SKCOI cells.
11would have been of interest to analyseallseven BSMabs in the inrilm
microcytostesis assay. However it was not the priority of this study. The mainobjective
wasto determine if HPLCcouldbe used to purifY these BSMahsandthen to select the
antibodies of most interest for evaluation in the future. :.• was only possible to evaluate
one cr tbe purifiedantibodies in the mlcrocvtostasis assay in this study due to
limitations in the amount of antibodiesavailable. In the future, to do the other
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hybridomas justice. therewould have 10 be much more ascitic Ouid produced for cach
ore . This should bea future goal for 26-7-35 in particular IS it showedgood dual
specificity activitybut could not beevaluatedin thein l!ilm microcytostasis assay
becausethere was insufficient purifiedproduct . IIW3S demonstrated in this studythai
four of the sevenprotein A purifiedhybridomas had very lowactivity in the dual
specificity assay. It is possible thai lhe immunoglobulin genesof these hybridomas have
mutated or have been lost with resultantloss of bispecifie activity. This is speculation
and it would have 10be verified by chromosomal analysis
Finally, the next step for 26-61-10is that it should be further evaluated for its
targeting potential in a preclinical inma model with SKeOI and COLO 320 DM
growing as xenografts in nude mice. If results from Ihis study were promising.then
Phase I clinicalevaluation would bewarranted in patients Theresultsobtainedin this
thesis have provided the necessary backgroundfor such eveluarionsin the fulure
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